<SEC-DOCUMENT>0001558370-24-012836.txt : 20240917
<SEC-HEADER>0001558370-24-012836.hdr.sgml : 20240917
<ACCEPTANCE-DATETIME>20240917091510
ACCESSION NUMBER:		0001558370-24-012836
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20240916
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240917
DATE AS OF CHANGE:		20240917

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CAPRICOR THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001133869
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34058
		FILM NUMBER:		241302723

	BUSINESS ADDRESS:	
		STREET 1:		8840 WILSHIRE BLVD
		STREET 2:		2ND FLOOR
		CITY:			BEVERLY HILLS
		STATE:			CA
		ZIP:			90211
		BUSINESS PHONE:		(310) 358-3200

	MAIL ADDRESS:	
		STREET 1:		8840 WILSHIRE BLVD
		STREET 2:		2ND FLOOR
		CITY:			BEVERLY HILLS
		STATE:			CA
		ZIP:			90211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nile Therapeutics, Inc.
		DATE OF NAME CHANGE:	20070920

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SMI PRODUCTS INC
		DATE OF NAME CHANGE:	20010206
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>capr-20240916x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.7.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 9/17/2024 12:49:26 AM -->
<!-- iXBRL Library version: 1.0.8923.15446 -->
<!-- iXBRL Service Job ID: 17dcd15b-c611-4f57-a60b-e17a786c44a6 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:capr="http://capricor.com/20240916" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" name="dei:EntityCentralIndexKey" id="Tc__u0mS83JvkawhwhGBn5PqA_1_1">0001133869</ix:nonNumeric><ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" name="dei:AmendmentFlag" id="Tc_A0isA7WEhUag8SFS4MovyQ_2_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="capr-20240916.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-16</xbrli:startDate><xbrli:endDate>2024-09-16</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><a id="_8ea9d98b_fd5b_482e_8270_ced16cc84f95"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" name="dei:DocumentType" id="Narr_hioGD5x-_kigBtJzNsz5Zg"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section 13 or 15(d) of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date of Report (Date of earliest event reported)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_Et_S-skv9kORqx98fSLjSA"><b style="font-weight:bold;">September 16, 2024</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:24pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" name="dei:EntityRegistrantName" id="Narr_WmmFSHtzyEy3wbHiyAiBVQ"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></ix:nonNumeric><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of Registrant as Specified in its Charter) </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><a id="_1f2dae61_4096_42f8_b63f_50791ccc1987"></a><a id="Tc_ZfkOBe_df0OsOGx96sJZvg_2_0"></a><a id="Tc_kDAbks7xo0epNkSvMgp65w_2_2"></a><a id="Tc_lroCP0Naj0Sly6uhVP64Sw_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:31.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_xkxd5fdwwEeSO-0tcAXBPQ_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" name="dei:EntityFileNumber" id="Tc_MF7c9jfp7ECE0x2FIG8v4g_1_2"><b style="font-weight:bold;">001-34058</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" name="dei:EntityTaxIdentificationNumber" id="Tc_EWLYZfCzY0CkOuwRtw7whg_1_4"><b style="font-weight:bold;">88-0363465</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:31.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">File Number)</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Identification No.)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" name="dei:EntityAddressAddressLine1" id="Narr_6Gwhytn1jEeQgZuucnTI_A"><b style="font-weight:bold;">10865 Road to the Cure, Suite 150</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" name="dei:EntityAddressCityOrTown" id="Narr_8bWrczrZqUK0z4S0x8Kcpg"><b style="font-weight:bold;">San Diego</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_qqv1dUPhU0i7q-WC-1YBug"><b style="font-weight:bold;">California</b></ix:nonNumeric><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" name="dei:EntityAddressPostalZipCode" id="Narr_WUmy4J3yFUutLlFcNnh1Qg"><b style="font-weight:bold;">92121</b></ix:nonNumeric><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" name="dei:CityAreaCode" id="Narr_8nF0O_Tw9Uen4tHeMYagYg"><b style="font-weight:bold;">858</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" name="dei:LocalPhoneNumber" id="Narr_qfdm4xQIfUGFm5RNqOK-qA"><b style="font-weight:bold;">727-1755</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code) </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Not Applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name or former address, if changed since last report) </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_ryqJ-MZvREaCKewdnI0nFg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_0IQtqsohekSxngTDnPDHdQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_Mm-3FuYyJEKQWym5f08LWQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_lAy6w3bZxECd1mo03_IQZQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:324pt;margin:0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr__Do9PBQPeUa_MsH8cx6j1A"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:6pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><a id="_1c0baf23_d0e6_4cdb_9993_8a8836d58abc"></a><a id="Tc_M6QR_57AOkaYyChnx6Cv3Q_1_0"></a><a id="Tc_fRPGl23SsEe18khK3RaBRg_1_2"></a><a id="Tc_-S3zxKxnOU6MQx3Qaq5g3Q_1_4"></a><a id="Tc_Pnu-xAA4sE6MNPO3-00Q2w_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.99%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;</p></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:bottom;width:1.99%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:32%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:32%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of Each Exchange on Which</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" name="dei:Security12bTitle" id="Tc_kDYCiCuE2U-QkViyARS4oQ_2_0">Common Stock, par value $0.001 per share</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" name="dei:TradingSymbol" id="Tc_70pryl74Ck6eGE8pZmr__w_2_2">CAPR</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The <ix:nonNumeric contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Narr_tt6wqBb86UGfl7LQUlhTSw">Nasdaq</ix:nonNumeric> Capital Market</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:50.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">Item 1.01</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Entry into a Material Definitive Agreement.   </b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercialization and Distribution Binding Term Sheet </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">On September 16, 2024, Capricor Therapeutics, Inc. (the &#8220;Company&#8221; or &#8220;Capricor&#8221;) entered into a Binding Term Sheet (the &#8220;Term Sheet&#8221;) with Nippon Shinyaku, Co., Ltd., a Japanese corporation, (&#8220;Nippon Shinyaku&#8221;) for the commercialization and distribution of deramiocel, the Company&#8217;s lead product candidate, for the treatment of Duchenne muscular dystrophy in the European region, as defined in the Term Sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">Subject to finalization of a Definitive Agreement, under the terms of the Term Sheet, Capricor will be responsible for the development and manufacturing of deramiocel for potential approval in the European region. Nippon Shinyaku will be responsible for the sales and distribution of deramiocel in the European region. Capricor will sell commercial product to Nippon Shinyaku and, in addition, will receive a double-digit share of product revenue and additional development and sales-based milestone payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">In addition, Nippon Shinyaku has agreed to invest $15.0 million for the purchase of common stock of the Company at a 20% premium based on the 60-day volume-weighted average price (&#8220;VWAP&#8221;) of the Company&#8217;s common stock through closing of market trading on September 16, 2024. Capricor will also receive an upfront payment of $20.0 million upon execution of the Definitive Agreement, with potential additional development and sales-based milestone payments of up to $715.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">The Company expects to file the Term Sheet as an exhibit to its Quarterly Report on Form 10-Q for the period ended September 30, 2024 and intends to seek confidential treatment for certain terms and provisions of the Term Sheet. The foregoing description is a summary of the material terms of the Term Sheet, does not purport to be complete, and is qualified in its entirety by reference to the text of the Term Sheet when filed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Private Placement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">On September 16, 2024, the Company entered into Subscription Agreement (the &#8220;Subscription Agreement&#8221;) with Nippon Shinyaku &#160;pursuant to which on September 16, 2024, the Company issued and sold to Nippon Shinyaku in a private placement (the &#8220;Private Placement&#8221;), an aggregate of 2,798,507 shares (the &#8220;Shares&#8221;) of the common stock of the Company, par value $0.001 per share (the &#8220;Common Stock&#8221;), at a price per Share of $5.36, which was issued at a 20% premium to the 60-day VWAP, for an aggregate purchase price of approximately $15.0 million. The Subscription Agreement also includes lock-up provisions restricting Nippon Shinyaku from selling or otherwise disposing of shares of Common Stock until the six month anniversary of the Closing Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">In connection with the Private Placement, the Company also entered into a Registration Rights Agreement with Nippon Shinyaku on September 16, 2024 (the &#8220;Registration Rights Agreement&#8221;). Pursuant to the terms of the Registration Rights Agreement, the Company is obligated (i) to prepare and file with the Securities and Exchange Commission (the &#8220;SEC&#8221;) a registration statement (the &#8220;Registration Statement&#8221;) to register for resale the Shares, and (ii) to use its reasonable best efforts to cause the Registration Statement to be declared effective by the SEC as soon as practicable, in each case subject to certain deadlines. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">The foregoing descriptions of the Subscription Agreement and the Registration Rights Agreement do not purport to be complete and are qualified in their entirety by reference to the form of Subscription Agreement and the Registration Rights Agreement, which are filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">The representations, warranties and covenants contained in the Subscription Agreement and the Registration Rights Agreement were made solely for the benefit of the parties to the Subscription Agreements and the Registration Rights Agreement and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Subscription Agreement and the Registration Rights Agreement are incorporated herein by reference only to provide investors with information regarding the terms of the Subscription Agreement and the Registration Rights Agreement and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company&#8217;s periodic reports and other filings with the SEC. &#160;</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:18pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">In connection with the Private Placement, and as part of the Subscription Agreement, the Company and Nippon Shinyaku further agreed to amend Section 2(e) of the Common Stock Purchase Warrant issued by the Company to Nippon Shinyaku on September 29, 2023. &#160;In that amendment, Nippon Shinyaku agreed that it shall not be permitted to exercise its right to purchase shares under the Common Stock Purchase Warrant to the extent that such exercise would cause Nippon Shinyaku to own more than 19.99 percent of the Company&#8217;s shares outstanding immediately after giving effect to such exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:50.4pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 3.02</b></span><b style="font-weight:bold;">Unregistered Sales of Equity Securities. &#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the Private Placement described in Item 1.01 of this Current Report on Form 8-K, which description is incorporated by reference into this Item 3.02 in its entirety, on September 16, 2024, the Company sold the Shares to an &#8220;accredited investor,&#8221; as that term is defined in the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act and corresponding provisions of state securities or &#8220;blue sky&#8221; laws. Nippon Shinyaku represented to the Company that it was an &#8220;accredited investor,&#8221; as defined in Regulation D, and was acquiring the Shares for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. Accordingly, the Shares have not been registered under the Securities Act and such Shares may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws. Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of Common Stock or other securities of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 7.01. Regulation FD Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 17, 2024, the Company issued a press release announcing the Term Sheet and the Private Placement. A copy of the press release has been furnished as Exhibit 99.1 hereto and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:50.4pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 9.01</b></span><b style="font-weight:bold;">Financial Statements and Exhibits. &#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">(d) Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:92.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:92.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="capr-20240916xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subscription Agreement.</span></a></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:92.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:92.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="capr-20240916xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement.</span></a></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:92.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:92.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="capr-20240916xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Letter of Intent.</span></a> </p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:92.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:92.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="capr-20240916xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, titled &#8220;Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy&#8221;, dated September 17, 2024</span></a>. </p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:92.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:92.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cover Page Interactive Data File (formatted as inline XBRL).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:18pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"/><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:&#160;&#160;September 17, 2024</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0pt 9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Linda Marb&#225;n, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt 0pt 0pt 9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Linda Marb&#225;n, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt 0pt 0pt 9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:18pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>capr-20240916xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 9/17/2024 12:49:24 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 10.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><i style="font-size:12pt;font-style:italic;">Execution Version</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">SIGNATURE PAGE TO SUBSCRIPTION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The undersigned has caused this Subscription Agreement to be duly executed by its authorized signatory as of the date of this Subscription Agreement as set forth in the Preamble below.</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">Nipp</p></div></div></td><td style="vertical-align:bottom;width:44.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:39.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Name of Investor:</font></p></td><td style="vertical-align:bottom;width:44.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Nippon Shinyaku Co., Ltd. </font></p></td><td style="vertical-align:bottom;width:39.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Signature:</font></p></td><td style="vertical-align:bottom;width:44.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">/s/ Takanori Edamitsu</font></p></td><td style="vertical-align:bottom;width:39.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Name (print):</font></p></td><td style="vertical-align:bottom;width:44.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Takanori Edamitsu</font></p></td><td style="vertical-align:bottom;width:39.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:bottom;width:44.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Director, Business Management &amp; Sustainability</font></p></td><td style="vertical-align:bottom;width:39.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Aggregate Purchase Price (Subscription Amount):</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">$</font></p></td><td colspan="2" style="vertical-align:bottom;width:47.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">15,000,000.00</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:30.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Number of Shares to be Acquired:</font></p></td><td style="vertical-align:bottom;width:19.15%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">2,798,507</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Tax ID No.:</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Not Applicable</font></p></td><td style="vertical-align:bottom;width:33.34%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Address for Notice/Residency of Investor:</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">c/o</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Nippon Shinyaku Co., Ltd. </font></p></td><td style="vertical-align:bottom;width:33.34%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Street:</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">14, Nishinosho-Monguchi-cho, Kisshoin, Minami-ku</font></p></td><td style="vertical-align:bottom;width:33.34%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">City/State/Zip:</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Kyoto 601-8550, Japan</font></p></td><td style="vertical-align:bottom;width:33.34%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Attention:</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Department Manager, Legal Department</font></p></td><td style="vertical-align:bottom;width:33.34%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Telephone No.:</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">(+81) 75 321 9104</font></p></td><td style="vertical-align:bottom;width:33.34%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Facsimile No.:</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">(+81) 75 321 9128</font></p></td><td style="vertical-align:bottom;width:33.34%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">E-mail Address:</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Delivery Instructions:</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">(if different than above)</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">c/o</font></p></td><td style="vertical-align:bottom;width:33.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Street:</font></p></td><td style="vertical-align:bottom;width:33.34%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">City/State/Zip:</font></p></td><td style="vertical-align:bottom;width:33.34%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Attention:</font></p></td><td style="vertical-align:bottom;width:33.34%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;">Telephone No.:</font></p></td><td style="vertical-align:bottom;width:33.34%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">[SIGNATURE PAGES CONTINUE]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">SIGNATURE PAGE TO SUBSCRIPTION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The undersigned has caused this Subscription Agreement to be duly executed by its authorized signatory as of the date of this Subscription Agreement as set forth in the Preamble below.</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:101%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:3.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:39.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:bottom;width:46.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Linda Marb&#225;n, Ph.D.</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:bottom;width:39.76%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Linda Marb&#225;n, Ph.D.</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:bottom;width:39.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Chief Executive Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:25.2pt;text-indent:-25.2pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-size:12pt;font-style:italic;">[Signature Page to Subscription Agreement]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">SUBSCRIPTION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This Subscription Agreement (this &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Subscription</font><font style="font-size:12pt;">&#8221;) is dated as of September 16, 2024, by and between </font><b style="font-size:12pt;font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b><font style="font-size:12pt;">, a Delaware corporation (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Company</font><font style="font-size:12pt;">&#8221;), and the investor identified on the signature page hereto (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Investor</font><font style="font-size:12pt;">&#8221;). The Company and the Investor are sometimes referred to herein as the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Parties</font><font style="font-size:12pt;">.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">A.</b></font><font style="font-size:12pt;">The Company wishes to issue and sell to the Investor, and the Investor wishes to purchase from the Company, upon the terms and conditions stated in this Subscription, 2,798,507 shares (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Shares</font><font style="font-size:12pt;">&#8221;) of Common Stock, par value $0.001 per share, of the Company (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Common Stock</font><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">B.</b></font><font style="font-size:12pt;">The Company and the Investor are executing and delivering this Subscription in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Securities Act</font><font style="font-size:12pt;">&#8221;), and Rule 506 of Regulation D (&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Regulation D</font><font style="font-size:12pt;">&#8221;) as promulgated by the United States Securities and Exchange Commission (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">SEC</font><font style="font-size:12pt;">&#8221;) under the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">C. </b></font><font style="font-size:12pt;">Concurrently with the execution of this Subscription, the Company and the Investor are entering into a separate registration rights agreement (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Registration Rights Agreement</font><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">NOW, THEREFORE, </b><font style="font-size:12pt;">in consideration of the mutual covenants contained in this Subscription, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Investor hereby agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">1.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions.</u><font style="font-size:12pt;"> As used in this Subscription, the following terms shall have the following respective meanings:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Accredited Investor Questionnaire</font><font style="font-size:12pt;">&#8221; shall have the meaning assigned to such term in 5(b).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Advisors</font><font style="font-size:12pt;">&#8221; shall have the meaning assigned to such term in Section 4(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Affiliate</font><font style="font-size:12pt;">&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Board of Directors</font><font style="font-size:12pt;">&#8221; means the board of directors of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Commission</font><font style="font-size:12pt;">&#8221; means the United States Securities and Exchange Commission.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Common Stock</font><font style="font-size:12pt;">&#8221; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Discussion Time</font><font style="font-size:12pt;">&#8221; shall have the meaning assigned to such term in Section 4(b).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Environmental Laws</font><font style="font-size:12pt;">&#8221; shall have the meaning assigned to such term in Section 3(m).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Evaluation Date</font><font style="font-size:12pt;">&#8221; shall have the meaning ascribed to such term in Section 3(s).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Exchange Act</font><font style="font-size:12pt;">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">FCPA</font><font style="font-size:12pt;">&#8221; means the Foreign Corrupt Practices Act of 1977, as amended.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">FDA</font><font style="font-size:12pt;">&#8221; shall have the meaning ascribed to such term in Section 3(ff).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">FDCA</font><font style="font-size:12pt;">&#8221; shall have the meaning ascribed to such term in Section 3(ff).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">GAAP</font><font style="font-size:12pt;">&#8221; shall have the meaning ascribed to such term in Section 3(h).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Hazardous Materials</font><font style="font-size:12pt;">&#8221; shall have the meaning assigned to such term in Section 3(m).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Intellectual Property Rights</font><font style="font-size:12pt;">&#8221; shall have the meaning ascribed to such term in Section 3(p).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Letter of Intent</font><font style="font-size:12pt;">&#8221; means the letter of intent dated as of September 16, 2024, by and between the Company and the Investor, with respect to the grant by the Company to the Investor of the exclusive right to distribute deramiocel for the treatment of Duchenne muscular dystrophy in Europe.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Liens</font><font style="font-size:12pt;">&#8221; means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Lock-Up Period</font><font style="font-size:12pt;">&#8221; shall have the meaning assigned to such term in Section 5(c).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Material Adverse Effect</font><font style="font-size:12pt;">&#8221; shall mean any change, event, circumstance, development, condition, occurrence or effect that, individually or in the aggregate, (a) is materially adverse to the business, financial condition, properties, assets, liabilities, stockholders&#8217; equity or results of operations of the Company and its Subsidiaries, taken as a whole, or (b) materially delays or materially impairs the ability of the Company to comply, or prevents the Company from complying, with its obligations under this Subscription, the other Transaction Documents, or with respect to the Closing or would reasonably be expected to do so; </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-size:12pt;">, that none of the following will be deemed in themselves, either alone or in combination, to constitute, and that none of the following will be taken into account in determining whether there has been or will be, a Material Adverse Effect under subclause (a) of this definition:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(i) any change generally affecting the economy, financial markets or political, economic or regulatory conditions in the United States or any other geographic region in which the Company conducts business, provided that the Company is not disproportionately affected thereby;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(ii) general financial, credit or capital market conditions, including interest rates or exchange rates, or any changes therein, provided that the Company is not disproportionately affected thereby;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(iii) any change that generally affects industries in which the Company and its Subsidiaries conduct business, provided that the Company is not disproportionately affected thereby;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(iv) earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, fires or other natural disasters, weather conditions, global pandemics, including the COVID-19 pandemic and related strains, epidemic or similar health emergency, and other force majeure events in the United States or any other location, provided that the Company is not disproportionately affected thereby;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(v) national or international political or social conditions (or changes in such conditions), whether or not pursuant to the declaration of a national emergency or war, or the occurrence of any military or terrorist attack, provided that the Company is not disproportionately affected thereby;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(vi) material changes in laws after the date of this Subscription; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(vii) in and of itself, any material failure by the Company to meet any published or internally prepared estimates of revenues, expenses, earnings or other economic performance for any period ending on or after the date of this Subscription (it being understood that the facts and circumstances giving rise to such failure may be deemed to constitute, and may be taken into account in determining whether there has been, a Material Adverse Effect to the extent that such facts and circumstances are not otherwise described in clauses (i)-(vi) of this definition).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Material Permits</font><font style="font-size:12pt;">&#8221; shall have the meaning ascribed to such term in Section 3(n).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Money Laundering Laws</font><font style="font-size:12pt;">&#8221; shall have the meaning ascribed to such term in Section 3(hh).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Person</font><font style="font-size:12pt;">&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Pharmaceutical Product</font><font style="font-size:12pt;">&#8221; shall have the meaning ascribed to such tern in Section 3(ff).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Proceeding</font><font style="font-size:12pt;">&#8221; means an action, claim, suit, investigation or proceeding.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#151515;font-size:12pt;">&#8220;</font><font style="color:#151515;font-size:12pt;font-style:italic;font-weight:bold;">Required Approvals</font><font style="color:#151515;font-size:12pt;">&#8221; shall have the meaning ascribed to such term in Section 3(e).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#151515;font-size:12pt;">&#8220;</font><font style="color:#151515;font-size:12pt;font-style:italic;font-weight:bold;">Rule 144</font><font style="color:#151515;font-size:12pt;">&#8221; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#151515;font-size:12pt;">&#8220;</font><font style="color:#151515;font-size:12pt;font-style:italic;font-weight:bold;">Securities Act</font><font style="color:#151515;font-size:12pt;">&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#151515;font-size:12pt;">&#8220;</font><font style="color:#151515;font-size:12pt;font-style:italic;font-weight:bold;">Shares</font><font style="color:#151515;font-size:12pt;">&#8221; means the shares of Common Stock issued or issuable to the Investor pursuant to this Subscription.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#151515;font-size:12pt;">&#8220;</font><font style="color:#151515;font-size:12pt;font-style:italic;font-weight:bold;">Short Sales</font><font style="color:#151515;font-size:12pt;">&#8221; means all &#8220;short sales&#8221; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include locating and/or borrowing shares of Common Stock).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#151515;font-size:12pt;">&#8220;</font><font style="color:#151515;font-size:12pt;font-style:italic;font-weight:bold;">Subscription Amount</font><font style="color:#151515;font-size:12pt;">&#8221; means, as to the Investor, the aggregate amount to be paid for Shares purchased hereunder as specified below such Investor&#8217;s name on the signature page of this Subscription and next to the heading &#8220;Subscription Amount,&#8221; in United States dollars and in immediately available funds.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#3f3f3f;font-size:12pt;">&#8220;</font><font style="color:#151515;font-size:12pt;font-style:italic;font-weight:bold;">Subsidiary</font><font style="color:#525252;font-size:12pt;">&#8221;</font><font style="color:#151515;font-size:12pt;"> means </font><font style="color:#282828;font-size:12pt;">any subsidiary of </font><font style="color:#151515;font-size:12pt;">the Company </font><font style="color:#282828;font-size:12pt;">as set </font><font style="color:#151515;font-size:12pt;">forth in the SEC </font><font style="color:#282828;font-size:12pt;">Reports</font><font style="color:#525252;font-size:12pt;">, </font><font style="color:#282828;font-size:12pt;">and shall</font><font style="color:#6e6e6e;font-size:12pt;">, </font><font style="color:#282828;font-size:12pt;">where applicable</font><font style="color:#6e6e6e;font-size:12pt;">, </font><font style="color:#282828;font-size:12pt;">also </font><font style="color:#151515;font-size:12pt;">include </font><font style="color:#282828;font-size:12pt;">any direct o</font><font style="color:#525252;font-size:12pt;">r </font><font style="color:#151515;font-size:12pt;">indirect </font><font style="color:#282828;font-size:12pt;">subsidiary of the Company formed o</font><font style="color:#525252;font-size:12pt;">r </font><font style="color:#282828;font-size:12pt;">acquired after the date hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Trading Market</font><font style="font-size:12pt;">&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Transaction Documents</font><font style="font-size:12pt;">&#8221; shall have the meaning assigned to such term under Section 4(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Transfer Agent</font><font style="font-size:12pt;">&#8221; means Equiniti Trust Company, LLC, the current transfer agent of the Company, and any successor transfer agent of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">2.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subscription</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">The Investor agrees to buy, and the Company agrees to sell and issue to the Investor, 2,798,507 Shares for an aggregate purchase price of $5.36 (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Subscription Amount</font><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">The completion of the purchase and sale of the Shares (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Closing</font><font style="font-size:12pt;">&#8221;) shall take place at the offices of Sidley Austin LLP, located at 1001 Page Mill Road, Building 1 Palo Alto, California 94304, or at such other location(s) or remotely by facsimile transmission or other electronic means as the parties may mutually agree, on September 20, 2024, or such other date mutually agreed upon by the Parties. At the Closing, (i)&#160;the Investor shall pay the Subscription Amount by wire transfer of immediately available funds to the Company to such bank account or accounts as shall be designated by the Company and (ii)&#160;the Company shall cause the Shares to be delivered to the Investor, with the delivery of the Shares to be made through book entry confirmation from the Company&#8217;s Transfer Agent.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">3.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties of the Company</u><font style="font-size:12pt;">. Except as set forth in the SEC Reports, which shall qualify any representation or otherwise made herein, but excluding any disclosures set</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">forth under the headings &#8220;Risk Factors,&#8221; or disclosure of risks set forth in any &#8220;forward-looking statements&#8221; disclaimer, or disclosures in any other statements that are similarly cautionary or predictive in nature, the Company hereby makes the following representations and warranties to the Investor:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsidiaries</u><font style="font-size:12pt;">. All of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports. Except as set forth in the SEC Reports, the Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organization and Qualification</u><font style="font-size:12pt;">. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not have or reasonably be expected to result in a Material Adverse Effect and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authorization; Enforcement</u><font style="font-size:12pt;">. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Subscription and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Subscription and each of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&#8217;s stockholders in connection herewith or therewith other than in connection with the Required Approvals (as defined below). This Subscription and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflicts</u><font style="font-size:12pt;">. The execution, delivery and performance by the Company of this Subscription and the other Transaction Documents to which it is a party, the issuance and sale of the Shares and the consummation by it of the transactions contemplated hereby and thereby do</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">not and will not (i) conflict with or violate any provision of the Company&#8217;s or any Subsidiary&#8217;s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as would not have or reasonably be expected to result in a Material Adverse Effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Filings, Consents and Approvals</u><font style="font-size:12pt;">. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant to Section 5(a) of this Subscription, (ii) application(s) to each applicable Trading Market for the listing of the Shares for trading thereon in the time and manner required thereby, (ii) such filings as are required to be made under applicable state securities laws and/or the rules of the Financial Industry Regulatory Authority, Inc., and (iii) the filing of the registration statement required to be filed by the Registration Rights Agreement (collectively, the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Required Approvals</font><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Issuance of the Securities; Registration</u><font style="font-size:12pt;">. The Shares are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, and free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant to this Subscription. Subject to the accuracy of the representations and warranties made by the Investor in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4</u><font style="font-size:12pt;"> hereof, the offer and sale of the Shares to the Investor is and will be, in compliance with applicable exemptions from (i) the registration and prospectus delivery requirements of the Securities Act and (ii) the registration and qualification requirements of applicable securities laws of the states of the United States.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capitalization</u><font style="font-size:12pt;">. The authorized capital stock of the Company consists of 100,000,000 shares of Common Stock and 5,000,000 shares of preferred stock, par value $0.001 per share. The Company&#8217;s disclosure of its issued and outstanding capital stock in the SEC Reports containing such disclosure was accurate in all material respects as of the date indicated in such SEC Reports. All of the issued and outstanding shares of Common Stock have been duly authorized and validly issued and are fully paid and non-assessable. None of the outstanding shares of capital stock of the Company were issued in violation of any preemptive or other similar rights of any securityholder of the Company which have not been waived.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(h)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SEC Reports; Financial Statements</u><font style="font-size:12pt;">. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the year preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein being collectively referred to herein as the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">SEC Reports</font><font style="font-size:12pt;">&#8221;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC Reports complied in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">GAAP</font><font style="font-size:12pt;">&#8221;), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(i)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Material Changes; Undisclosed Events, Liabilities or Developments</u><font style="font-size:12pt;">. Since the date of the most recent unaudited financial statements included within the SEC Reports, except as disclosed in the SEC Reports, (i) there has been no event, occurrence or development that has had or that would reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any material liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company&#8217;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company equity plans or arrangements.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(j)</font></font><font style="font-size:12pt;"> </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Litigation</u><font style="font-size:12pt;">. There is no Proceeding and, to the knowledge of the Company, there is no threatened Proceeding which (i) could adversely affect or challenge the legality, validity or enforceability of any of the Transaction Documents or the Shares or (ii) would, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof (in his or her capacity as such), is or has been the subject of any Proceeding involving a claim of violation or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Company (in his or her capacity as such). The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#232323;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(k)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Labor Relations</u><font style="font-size:12pt;">. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which would reasonably be expected to result in a Material Adverse Effect. None of the Company&#8217;s or its Subsidiaries&#8217; employees is a member of a union that relates to such employee&#8217;s relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#232323;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(I)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance</u><font style="font-size:12pt;">. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received written notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as would not have or reasonably be expected to result in a Material Adverse Effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(m)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Environmental Laws</u><font style="font-size:12pt;">. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Hazardous Materials</font><font style="font-size:12pt;">&#8221;) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Environmental Laws</font><font style="font-size:12pt;">&#8221;); (ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply would be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(n)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Permits</u><font style="font-size:12pt;">. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except where the failure to possess such permits would not reasonably be expected to result in a Material Adverse Effect (&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Material Permits</font><font style="font-size:12pt;">&#8221;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(o)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title to Assets</u><font style="font-size:12pt;">. The Company and the Subsidiaries have good and marketable title in all real and personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries, (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties and (iii) Liens that would not, individually or in the aggregate, have or reasonably be expected to have a Material Adverse Event. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance in all material respects.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(p)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property</u><font style="font-size:12pt;">. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and where the failure to so have would have a Material Adverse Effect (collectively, the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Intellectual Property Rights</font><font style="font-size:12pt;">&#8221;). Neither the Company nor any Subsidiary has received a written notice that any of the material Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Subscription, other than in accordance with the terms of the Intellectual Property Rights. Neither the Company nor any Subsidiary has received, since the date of the most recent unaudited financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as would not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(q)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insurance</u><font style="font-size:12pt;">. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">and customary in the businesses in which the Company and the Subsidiaries are engaged. Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(r)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Related Person Transactions</u><font style="font-size:12pt;">. There are no business relationships or related person transactions, as defined in Item 404 of Regulation S-K under the Exchange Act, involving the Company or any Subsidiary or any other person required to be described in the SEC Reports which have not been described as required.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(s)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sarbanes-Oxley; Internal Accounting Controls</u><font style="font-size:12pt;">. The Company and the Subsidiaries are in compliance in all material respects with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&#8217;s general or specific authorization , (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules and forms. The Company&#8217;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Evaluation Date</font><font style="font-size:12pt;">&#8221;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(t)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Fees</u><font style="font-size:12pt;">. Except for fees and commissions payable by the Company to a placement agent, if any, in connection with this transaction, no brokerage or finder&#8217;s fees or commissions are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Investor shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(u)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investment Company</u><font style="font-size:12pt;">. The Company is not, and immediately after receipt of payment for the Shares will not be, an &#8220;investment company&#8221; within the meaning of the Investment Company Act of 1940, as amended.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(v)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registration Rights</u><font style="font-size:12pt;">. Except as set forth in the SEC Reports and the Transaction Documents, no Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(w)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Listing and Maintenance Requirements</u><font style="font-size:12pt;">. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. Except as set forth in the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(x)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure</u><font style="font-size:12pt;">. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided the Investor or its agents or counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in the Transaction Documents. The Company is not in possession of any material non-public information with respect to the Company (other than the transaction contemplated by the Transaction Documents) immediately prior to the execution of this Agreement. The Company understands and confirms that the Investor will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Investor regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby is true and correct in all material respects and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading (it being understood that such disclosure furnished by or on behalf of the Company to the Investor includes the SEC Reports). The Company acknowledges and agrees that the Investor does not make or has not made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 4 hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(y)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Integrated Offering</u><font style="font-size:12pt;">. Assuming the accuracy of the Investor&#8217;s representations and warranties set forth in Section 4, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Shares to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(z)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Status</u><font style="font-size:12pt;">. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except for such taxes, if any, as are being contested in good faith and as to which adequate reserves have been established by the Company and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(aa)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Foreign Corrupt Practices</u><font style="font-size:12pt;">. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 0pt 30.25pt;"><font style="font-size:12pt;margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(bb)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accountants</u><font style="font-size:12pt;">. The Company&#8217;s accounting firm is Rose, Snyder &amp; Jacobs LLP. To the knowledge and belief of the Company, such accounting firm is a registered public accounting firm as required by the Exchange Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 0pt 30.25pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(cc)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acknowledgement Regarding Investor&#8217;s Purchase of Securities</u><font style="font-size:12pt;">. The Company acknowledges and agrees that the Investor is acting solely in the capacity of an arm&#8217;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that the Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by the Investor or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Investor&#8217;s purchase of the Shares. The Company further represents to each Investor that the Company&#8217;s decision to enter into this Subscription and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 0pt 30.25pt;"><font style="font-size:12pt;margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(dd)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acknowledgment Regarding Investor&#8217;s Trading Activity</u><font style="font-size:12pt;">. Anything in this Subscription or elsewhere herein to the contrary notwithstanding (except for Sections 4(b) and 5(a)), it is understood and acknowledged by the Company that: (i) the Investor has not been asked by the Company to agree, nor has the Investor agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or &#8220;derivative&#8221; securities based on securities issued by the Company or to hold the Shares for any specified term; (ii) past or future open market or other transactions by the Investor, specifically including, without limitation, Short Sales or &#8220;derivative&#8221; </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company&#8217;s publicly-traded securities; (iii) the Investor, and counter-parties in &#8220;derivative&#8221; transactions to which the Investor is a party, directly or indirectly, presently may have a &#8220;short&#8221; position in the Common Stock, and (iv) the Investor shall not be deemed to have any affiliation with or control over any arm&#8217;s length counter-party in any &#8220;derivative&#8221; transaction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 0pt 30.25pt;"><font style="font-size:12pt;margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(ee)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulation M Compliance</u><font style="font-size:12pt;">. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Shares, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Shares, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the placement agent, if any, in connection with the placement of the Shares.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 0pt 30.25pt;"><font style="font-size:12pt;margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(ff)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FDA</u><font style="font-size:12pt;">. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">FDA</font><font style="font-size:12pt;">&#8221;) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">FDCA</font><font style="font-size:12pt;">&#8221;) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Pharmaceutical Product</font><font style="font-size:12pt;">&#8221;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company&#8217;s knowledge, threatened in writing, Proceeding against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(gg)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Office of Foreign Assets Control</u><font style="font-size:12pt;">. Neither the Company nor any Subsidiary nor, to the Company&#8217;s knowledge, any director, officer, agent, employee or affiliate of the </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">OFAC</font><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 0pt 30.25pt;"><font style="font-size:12pt;margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(hh)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Money Laundering</u><font style="font-size:12pt;">. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Money Laundering Laws</font><font style="font-size:12pt;">&#8221;), and no Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened in writing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 0pt 30.25pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(ii)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Committee on Foreign Investment</u><font style="font-size:12pt;">. The Company does not engage in the design, fabrication, development, testing, production or manufacture of one or more &#8220;critical technologies&#8221; within the meaning of the Defense Production Act of 1950, as amended, including all implementing regulations thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">4.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations, Warranties and Acknowledgments of the Investor</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">The Investor hereby represents and warrants as of the date hereof to the Company as follows: (i)&#160;it has the full right, power and authority to enter into this Subscription and to perform all of its obligations hereunder; (ii)&#160;this Subscription has been duly authorized and executed by the Investor and, when delivered in accordance with the terms hereof, will constitute a valid and binding agreement of the Investor enforceable against the Investor in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the rights and remedies of creditors generally or subject to general principles of equity; (iii)&#160;the execution and delivery of this Subscription and the consummation of the transactions contemplated hereby do not conflict with or result in a breach of the Investor&#8217;s governing or organizational documents; (iv)&#160;at the time the Investor was offered the Shares, it was, and at the date hereof it is, and on the date of the Closing it will be, an &#8220;accredited investor&#8221; as defined in Rule 501(a)&#160;under the Securities Act; (v) the Investor is knowledgeable, sophisticated and experienced in making, and is qualified to make, decisions with respect to investments in securities representing an investment decision like that involved in the purchase of the Shares; (vi)&#160;the Investor and the Investor&#8217;s attorneys, accountants, purchaser representatives and/or tax advisors, if any (collectively, &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Advisors</font><font style="font-size:12pt;">&#8221;), have received and carefully reviewed each of </font><font style="font-size:12pt;">this Subscription, and the exhibits attached hereto, including the Accredited Investor Questionnaire (as defined below) and any other documents or agreements explicitly contemplated hereunder, including the documents to be executed and delivered pursuant to Section 6 hereof (collectively, the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Transaction Documents</font><font style="font-size:12pt;">&#8221;)</font><font style="font-size:12pt;"> and all other documents requested by the Investor or its Advisors, if any, and understand the information contained therein, prior to the execution of this Subscription; (vii)&#160;the Investor and its Advisors, if any, have had a reasonable opportunity to ask questions of and receive answers from the Company&#8217;s officers and any other persons authorized by the Company to answer such questions, concerning, among other related matters, the Shares, the Transaction Documents and the business, financial condition, results of operations and prospects of the Company and all such questions have been answered by the Company to the full satisfaction of the Investor and its Advisors, if any; (viii)&#160;the Investor has taken no action which would give rise to any claim by any person for brokerage commissions, </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">finders&#8217; fees or the like relating to this Subscription or the transactions contemplated hereby; (ix)&#160;the Investor is not relying on the Company or any of its respective employees or agents with respect to the legal, tax, economic and related considerations of an investment in the Shares, and the Investor has relied on the advice of, or has consulted with, only its own Advisors; (x)&#160;the Investor is satisfied that it has received adequate information with respect to all matters which it or its Advisors, if any, consider material to its decision to make an investment in the Shares; (xi)&#160;except as set forth below, the Investor is not a, and it has no direct or indirect affiliation or association with any, member of the Financial Industry Regulatory Authority, Inc. or an Associated Person (as such term is defined under the NASD Membership and Registration Rules&#160;Section&#160;1011) as of the date hereof; and (xii) after giving effect to the amendment to Common Stock Purchase Warrant set forth in Section 8 hereof, the Investor did not acquire, nor obtained the right to acquire, twenty percent (20%) or more of the Common Stock (or securities convertible into or exercisable for Common Stock) or the voting power of the Company on a post-transaction basis.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">The Investor hereby also represents and warrants as of the date hereof to the Company that, other than the transactions contemplated hereunder, the Investor has not, directly or indirectly, nor has any person acting on behalf of or pursuant to any understanding with the Investor, executed any transactions in securities of the Company, including &#8220;short sales&#8221; as defined in Rule&#160;200 of Regulation&#160;SHO under the Securities Exchange Act of 1934, as amended (&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Short Sales</font><font style="font-size:12pt;">&#8221;), during the period commencing from the time that the Investor first became aware of the proposed transactions contemplated hereunder until the date hereof (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Discussion Time</font><font style="font-size:12pt;">&#8221;). The Investor has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">5.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Agreements of the Parties</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</u><font style="font-size:12pt;">. The Investor hereby covenants that until such time as the transactions contemplated by this Subscription are publicly disclosed by the Company through a press release and/or Current Report on Form&#160;8-K, the Investor will maintain the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accredited Investor Questionnaire</u><font style="font-size:12pt;">. Prior to the Closing, the Investor shall have executed, truthfully completed and delivered to the Company an Accredited Investor Questionnaire substantially in the form of </font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</b><font style="font-size:12pt;"> hereto (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Accredited Investor Questionnaire</font><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Market Stand-Off Agreement</u><font style="font-size:12pt;">. The Investor hereby agrees that it will not, without the prior written consent of the Company, during the period commencing on the date of the Closing, and ending 180 days following such date (such period, the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Lock-Up Period</font><font style="font-size:12pt;">&#8221;), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock (whether such shares or any such securities are then owned by the Investor or are thereafter acquired) or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">of ownership of such securities (these actions, collectively, &#8220;Transfer&#8221;), whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">The restrictions set forth herein shall not apply to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">any Transfers made by the Investor as a bona fide gift to a charity or educational institution;;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">any Transfers to any shareholder, partner or member of, or owner of a similar equity interest in, the Investor, as the case may be, if, in any such case, such transfer is not for value; and</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 0pt 30.25pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">any Transfer made by the Investor (a) in connection with the sale or other bona fide transfer in a single transaction of all or substantially all of the Investor&#8217;s share capital, partnership interests, membership interests or other similar equity interests, as the case may be, or all or substantially all of the Investor&#8217;s assets, in any such case not undertaken for the purpose of avoiding the restrictions imposed by this Agreement or (b) to another affiliated entity in connection with a corporate restructuring or reorganization transaction.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 90pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer Restrictions</u><font style="font-size:12pt;">.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:79.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Laws</u><font style="font-size:12pt;">. In addition to other restrictions set forth in this </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5</u><font style="font-size:12pt;">, the Investor covenants that the Shares may be disposed of only pursuant to an effective registration statement under, and in compliance with the requirements of, the Securities Act, or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, and in compliance with any applicable state and federal securities laws. In connection with any transfer of the Shares other than (i)&#160;pursuant to an effective registration statement, (ii)&#160;to the Company, or (iii)&#160;pursuant to Rule 144 (</font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">&#160;that the Investor provides the Company with reasonable assurances (in the form of seller and, if applicable, broker representation letters) that the Shares may be sold pursuant to such rule), the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Shares under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Subscription by executing a joinder agreement to each of the same, and shall have the rights of the Investor under this Subscription with respect to such transferred Shares upon such execution.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:79.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">(ii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Legends</u><font style="font-size:12pt;">. Book entry confirmations evidencing the Shares shall bear any legend as required by the &#8220;blue sky&#8221; laws of any state and a restrictive legend in substantially the following form, until such time as they are not required, as reasonably determined by the Company:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">THESE SHARES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), OR APPLICABLE STATE SECURITIES LAWS. THE SHARES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SHARES UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS TRANSFER AGENT OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">6.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Deliveries</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">On or prior to the Closing (except as indicated below), the Company shall deliver or cause to be delivered to each Purchaser the following:</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><font style="font-size:12pt;">this Agreement duly executed by the Company;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><font style="font-size:12pt;">the Registration Rights Agreement duly executed by the Company;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><font style="font-size:12pt;">the Letter of Intent duly executed by the Company;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font><font style="font-size:12pt;">a certificate, in form and substance reasonably satisfactory to the Investor, dated as of applicable Closing and signed by the Chief Executive Officer of the Company certifying as to the fulfillment of the conditions set forth in Section 7;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font><font style="font-size:12pt;">a certificate, in form and substance reasonably satisfactory to the Investor, of the Secretary of the Company, dated as of the applicable Closing, (a) certifying the resolutions adopted by the Board of Directors of the Company or a duly authorized committee thereof approving the transactions contemplated by this Agreement and the issuance of the Shares, (b) certifying the current versions of the certificate of incorporation, as amended, and bylaws of the Company and (c) certifying as to the signatures and authority of persons signing this Agreement and related documents on behalf of the Company; and</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(vi)</font><font style="font-size:12pt;">any related documents and such other documents as may be reasonably requested by the Investor.</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">On or prior to the Closing, the Investor shall deliver or cause to be delivered to the Company the following:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(i)</font></font><font style="font-size:12pt;">this Agreement duly executed by the Investor;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(ii)</font></font><font style="font-size:12pt;">the Registration Rights Agreement duly executed by the Investor; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(iii)</font></font><font style="font-size:12pt;">the Letter of Intent duly executed by the Investor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">7.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing Conditions</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><font style="font-size:12pt;">the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) on the Closing of the representations and warranties of the Investor contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><font style="font-size:12pt;">the obligations, covenants and agreements of the Investor required to be performed at or prior to the Closing shall have been performed in all material respects; and</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><font style="font-size:12pt;">the delivery by the Investor of the items set forth in Section 6(b) of this Agreement.</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">The respective obligations of the Investor hereunder in connection with the Closing are subject to the following conditions being met:</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><font style="font-size:12pt;">the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and on the Closing of the representations and warranties of the Company contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><font style="font-size:12pt;">the obligations, covenants and agreements of the Company required to be performed at or prior to the Closing shall have been performed in all material respects;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><font style="font-size:12pt;">the delivery by the Company of the items set forth in Section 6(a) of this Agreement;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font><font style="font-size:12pt;">there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font><font style="font-size:12pt;">from the date hereof to the Closing, trading in the Common Stock shall not have been suspended by the Commission or the Company&#8217;s principal Trading Market.</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">8.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment of Common Stock Purchase Warrant.</u><font style="font-size:12pt;"> As of the date hereof, Section 2(e) of that certain Common Stock Purchase Warrant issued by the Company to the Investor or its assigns on September 29, 2023, to purchase up to 2,145,922 shares of common stock, par value $0.001 per share at an exercise price of $5.70 per share, subject to certain adjustments therein, is hereby amended in its entirety as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(e) </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Holder&#8217;s Exercise Limitations</u><font style="font-size:12pt;">. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;Attribution Parties&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant but shall exclude the number of shares of Common Stock which would be issuable upon the exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;Beneficial Ownership Limitation&#8221; shall be 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 19.99% of the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">9.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">This Subscription constitutes the entire understanding and agreement among the parties with respect to its subject matter, and there are no agreements or understandings with respect to the subject matter hereof which are not contained in this Subscription.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">This Subscription may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and shall become effective when counterparts have been signed by each party and delivered to the other party hereto, it being understood that the parties need not sign the same counterpart. Execution may be made by delivery by facsimile or by e-mail delivery of a &#8220;.pdf&#8221; format data file.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">The provisions of this Subscription are severable and, in the event that any court or officials of any regulatory agency of competent jurisdiction shall determine that any one or more of the provisions or part of the provisions contained in this Subscription shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision or part of a provision of this Subscription and this Subscription shall be reformed and construed as if such invalid or illegal or unenforceable provision, or part of such provision, had never been contained herein, so that such provisions would be valid, legal and enforceable to the maximum extent possible, so long as such construction does not materially adversely affect the economic rights of either party hereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:12pt;">All communications hereunder, except as may be otherwise specifically provided herein, shall be in writing and shall be mailed, hand delivered, sent by a recognized overnight courier or sent via facsimile or by e-mail delivery and confirmed by letter, to the party to whom it is addressed at the following addresses or such other address as such party may advise the other in writing:</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:39.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">If to the Company:</font></p></td><td style="vertical-align:bottom;width:60.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Capricor Therapeutics, Inc.</font></p></td></tr><tr><td style="vertical-align:bottom;width:39.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:60.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">10865 Road to the Cure, Suite 150</font></p></td></tr><tr><td style="vertical-align:bottom;width:39.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:60.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">San Diego, CA 92121</font></p></td></tr><tr><td style="vertical-align:bottom;width:39.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:60.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Attention: General Counsel</font></p></td></tr><tr><td style="vertical-align:bottom;width:39.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:60.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Email Address: kkrasney@capricor.com</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">With a copy to (which shall not constitute notice):</font></p></td></tr><tr><td style="vertical-align:bottom;width:39.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:60.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:39.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:60.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Sidley Austin LLP</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:60.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:60.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">1001 Page Mill Road, Building 1</font></p></td></tr><tr><td style="vertical-align:bottom;width:39.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:60.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Palo Alto, CA 94304</font></p></td></tr><tr><td style="vertical-align:bottom;width:39.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:60.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Attention: Rob R. Carlson, Esq.</font></p></td></tr><tr><td style="vertical-align:bottom;width:39.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:60.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Email Address: rob.carlson@sidley.com</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">If to the Investor: as set forth on the Investor&#8217;s signature page hereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">All notices hereunder shall be effective upon receipt by the party to which it is addressed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(e)</font></font><font style="font-size:12pt;">No provision of this Subscription may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and the Investor or, in the case of a waiver, by the party against whom enforcement of any such waiver is sought. No waiver of any default with respect to any provision, condition or requirement of this Subscription shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(f)</font></font><font style="font-size:12pt;">This Subscription shall be governed by and interpreted in accordance with the laws of the State of Delaware for contracts to be wholly performed in such state and without giving effect to the principles thereof regarding the conflict of laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-size:12pt;font-style:italic;">[Remainder of Page Intentionally Left Blank]</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>capr-20240916xex10d2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 9/17/2024 12:49:24 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit&#160;10.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><i style="font-size:12pt;font-style:italic;">Execution Version</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">REGISTRATION RIGHTS AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This Registration Rights Agreement (this &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Agreement</font><font style="font-size:12pt;">&#8221;) is made and entered into as of </font><font style="font-size:12pt;">September 16, 2024</font><font style="font-size:12pt;">, by and among </font><b style="font-size:12pt;font-weight:bold;">CAPRICOR THERAPEUTICS</b><b style="font-size:12pt;font-weight:bold;">, INC.</b><font style="font-size:12pt;">, a Delaware corporation (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Company</font><font style="font-size:12pt;">&#8221;), and </font><font style="font-size:12pt;">each other party identified on the signature pages hereto</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This Agreement is made </font><font style="font-size:12pt;">in connection with those certain Subscription Agreements</font><font style="font-size:12pt;"> (</font><font style="font-size:12pt;">collectively, </font><font style="font-size:12pt;">the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Subscription</font><font style="font-size:12pt;font-style:italic;font-weight:bold;"> Agreement</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">s</font><font style="font-size:12pt;">&#8221;), </font><font style="font-size:12pt;">in each case, </font><font style="font-size:12pt;">dated as of the date hereof, by and </font><font style="font-size:12pt;">between</font><font style="font-size:12pt;"> the Company and </font><font style="font-size:12pt;">the investor identified on the signature pages </font><font style="font-size:12pt;">thereto (each</font><font style="font-size:12pt;"> such investor,</font><font style="font-size:12pt;"> a</font><font style="font-size:12pt;">n</font><font style="font-size:12pt;"> &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Investor</font><font style="font-size:12pt;">&#8221; and</font><font style="font-size:12pt;">,</font><font style="font-size:12pt;"> collectively, the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Investors</font><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">NOW, THEREFORE, IN CONSIDERATION</b><font style="font-size:12pt;"> of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each of the Holders </font><font style="font-size:12pt;">(as defined below) </font><font style="font-size:12pt;">agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">1.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u><font style="font-size:12pt;">. As used in this Agreement, the following terms shall have the following meanings:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Advice</font><font style="font-size:12pt;">&#8221; has the meaning set forth in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6(</u><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">c</u><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">)</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Affiliate</font><font style="font-size:12pt;">&#8221; means, with respect to any Person, any other person which directly or indirectly controls, is controlled by, or is under common control with, such Person; as such terms are used in and construed under Rule 405 of the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Agreement</font><font style="font-size:12pt;">&#8221; has the meaning set forth in the Preamble.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Business Day</font><font style="font-size:12pt;">&#8221; means any day except Saturday, Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Closing Date</font><font style="font-size:12pt;">&#8221; </font><font style="font-size:12pt;">means the date on which the completion of the purchases and sales of the Shares pursuant to the Subscription Agreements occurs; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, that if the purchases and sales of the Shares pursuant to the Subscription Agreements do not occur on a single date, the Closing Date shall be the date on which the last purchase and sale of Shares pursuant to a Subscription Agreement occurs</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Commission</font><font style="font-size:12pt;">&#8221; means the Securities and Exchange Commission.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Common Stock</font><font style="font-size:12pt;">&#8221; means the common stock of the Company, par value $0.0</font><font style="font-size:12pt;">0</font><font style="font-size:12pt;">1 per share, and any securities into which such common stock may hereinafter be reclassified.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Company</font><font style="font-size:12pt;">&#8221; has the meaning set forth in the Preamble.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-size:12pt;">&#8221; means each date that the Registration Statement filed pursuant to </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2(a)</u><font style="font-size:12pt;"> and any post-effective amendment thereto is declared effective by the Commission.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Effectiveness Deadline</font><font style="font-size:12pt;">&#8221; means, with respect to the Initial Registration Statement or the New Registration Statement, the 60</font><sup style="font-size:9pt;vertical-align:top;">th </sup><font style="font-size:12pt;">calendar day following the Closing Date (or, in the event the Commission reviews and has written comments to the Initial Registration Statement or the New Registration Statement, the </font><font style="font-size:12pt;">120</font><sup style="font-size:9pt;vertical-align:top;">th </sup><font style="font-size:12pt;">calendar day following the Closing Date);</font><i style="font-size:12pt;font-style:italic;"> provided, however,</i><font style="font-size:12pt;"> that if the Effectiveness Deadline falls on a Saturday, Sunday or other day that the Commission is closed for business, the Effectiveness Deadline shall be extended to the next Business Day on which the Commission is open for business.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Effectiveness Period</font><font style="font-size:12pt;">&#8221; has the meaning set forth in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2(b)</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Exchange Act</font><font style="font-size:12pt;">&#8221; means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations promulgated thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Filing Deadline</font><font style="font-size:12pt;">&#8221; means, with respect to the Initial Registration Statement required to be filed pursuant to </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2(a)</u><font style="font-size:12pt;">, the </font><font style="font-size:12pt;">30</font><sup style="font-size:9pt;vertical-align:top;">th </sup><font style="font-size:12pt;">calendar day following the Closing Date;</font><i style="font-size:12pt;font-style:italic;"> provided, however,</i><font style="font-size:12pt;"> that if the Filing Deadline falls on a Saturday, Sunday or other day that the Commission is closed for business, the Filing Deadline shall be extended to the next business day on which the Commission is open for business.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">FINRA</font><font style="font-size:12pt;">&#8221; has the meaning set forth in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3(</u><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">h</u><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">)</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Holder</font><font style="font-size:12pt;">&#8221; or &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Holders</font><font style="font-size:12pt;">&#8221; means the holder or holders, as the case may be, from time to time of Registrable Securities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Indemnified Party</font><font style="font-size:12pt;">&#8221; has the meaning set forth in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5(c)</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Indemnifying Party</font><font style="font-size:12pt;">&#8221; has the meaning set forth in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5(c)</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Initial Registration Statement</font><font style="font-size:12pt;">&#8221; means the initial Registration Statement filed pursuant to </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2(a)</u><font style="font-size:12pt;"> of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Investor</font><font style="font-size:12pt;">&#8221; or &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Investor</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">s</font><font style="font-size:12pt;">&#8221; has the meaning set forth in the </font><font style="font-size:12pt;">Preamble</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Losses</font><font style="font-size:12pt;">&#8221; has the meaning set forth in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5(a)</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">New Registration Statement</font><font style="font-size:12pt;">&#8221; has the meaning set forth in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2(a)</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Person</font><font style="font-size:12pt;">&#8221; means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Principal Market</font><font style="font-size:12pt;">&#8221; means the Trading Market on which the Common Stock is primarily listed and quoted for trading, which, as of the </font><font style="font-size:12pt;">date hereof</font><font style="font-size:12pt;">, </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;"> the </font><font style="font-size:12pt;">Nasdaq Capital Market</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Proceeding</font><font style="font-size:12pt;">&#8221; means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding, such as a deposition), whether commenced or threatened.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Prospectus</font><font style="font-size:12pt;">&#8221; means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated under the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Registrable Securities</font><font style="font-size:12pt;">&#8221; means all of the Shares</font><font style="font-size:12pt;"> and</font><font style="font-size:12pt;"> any securities issued or issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing;</font><i style="font-size:12pt;font-style:italic;"> provided</i><font style="font-size:12pt;">, that the Holder has completed and delivered to the Company a Selling Stockholder Questionnaire; and</font><i style="font-size:12pt;font-style:italic;"> provided, further</i><font style="font-size:12pt;">, that with respect to a particular Holder, such Holder&#8217;s Shares shall cease to be Registrable Securities upon the earliest to occur of the following: (</font><font style="font-size:12pt;">a</font><font style="font-size:12pt;">) a sale pursuant to a Registration Statement or Rule 144 under the Securities Act (in which case, only such security sold by the Holder shall cease to be a Registrable Security); or (</font><font style="font-size:12pt;">b</font><font style="font-size:12pt;">) such securities becoming eligible for resale by the Holder under Rule 144 without the requirement for the Company to be in compliance with the current public information requirement thereunder and without volume or manner-of-sale restrictions, pursuant to a written opinion letter to such effect, addressed, delivered and acceptable to the Transfer Agent.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Registration Statements</font><font style="font-size:12pt;">&#8221; means any one or more registration statements of the Company filed under the Securities Act that covers the resale of any of the Registrable Securities pursuant to the provisions of this Agreement (including, without limitation, the Initial Registration Statement, the New Registration Statement and any Remainder Registration Statements), including (in each case) the amendments and supplements to such Registration Statements, including pre- and post-effective amendments thereto, all exhibits and all material incorporated by reference or deemed to be incorporated by reference in such Registration Statements.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Remainder Registration Statement</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">s</font><font style="font-size:12pt;">&#8221; has the meaning set forth in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2(a)</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Rule 144</font><font style="font-size:12pt;">&#8221; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such rule.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Rule 415</font><font style="font-size:12pt;">&#8221; means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such rule.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Rule 424</font><font style="font-size:12pt;">&#8221; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such rule.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">SEC Guidance</font><font style="font-size:12pt;">&#8221; means (a) any publicly-available written or oral guidance, comments, requirements or requests of the Commission staff, </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, that any such oral guidance,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">comments, requirements or requests are reduced to writing by the Commission, and (b) the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Securities Act</font><font style="font-size:12pt;">&#8221; means the Securities Act of 1933, as amended, or any successor statute, and the rules and regulations promulgated thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Selling Stockholder Questionnaire</font><font style="font-size:12pt;">&#8221; means a questionnaire in the form attached as </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex B</u><font style="font-size:12pt;"> hereto, or such other form of questionnaire as may reasonably be adopted by the Company from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Shares</font><font style="font-size:12pt;">&#8221; means the shares of Common Stock issued or issuable to the </font><font style="font-size:12pt;">Investor</font><font style="font-size:12pt;">s pursuant to the </font><font style="font-size:12pt;">Subscription Agreements or any other agreement prior to the date hereof, including any share of Common Stock and related Warrants to Purchase Common Stock pursuant to the Securities Purchase Agreement dated September 29, 2023</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Subscription</font><font style="font-size:12pt;font-style:italic;font-weight:bold;"> Agreement</font><font style="font-size:12pt;">&#8221; </font><font style="font-size:12pt;">or &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Subscription Agreements</font><font style="font-size:12pt;">&#8221; </font><font style="font-size:12pt;">has the meaning set forth in the </font><font style="font-size:12pt;">Preamble</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Trading Day</font><font style="font-size:12pt;">&#8221; </font><font style="font-size:12pt;">means (a)&#160;a day on which the Common Stock is listed or quoted and traded on its Principal Trading Market (other than the OTC Markets Group Inc.), or (b)&#160;if the Common Stock is not listed on a Trading Market (other than the OTC Markets Group Inc.), a day on which the Common Stock is traded in the over-the-counter market, as reported by the OTC Markets Group Inc. (or any similar organization or agency succeeding to its functions of reporting prices);&#160;</font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, that in the event that the Common Stock is not listed or quoted as set forth in (a)&#160;or (b)&#160;hereof, then Trading Day shall mean a Business Day</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Trading Market</font><font style="font-size:12pt;">&#8221; means whichever of the </font><font style="font-size:12pt;">Nasdaq</font><font style="font-size:12pt;"> Global Select Market, the </font><font style="font-size:12pt;">Nasdaq</font><font style="font-size:12pt;"> Global Market, the </font><font style="font-size:12pt;">Nasdaq</font><font style="font-size:12pt;"> Capital Market or the </font><font style="font-size:12pt;">OTC Bulletin Board, the OTCQX Marketplace or the OTCQB Marketplace operated by the </font><font style="font-size:12pt;">OTC Markets</font><font style="font-size:12pt;"> Group Inc.</font><font style="font-size:12pt;"> on which the Common Stock is listed or quoted for trading on the date in question.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">2.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registration</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">On or prior to the Filing Deadline, the Company shall prepare and file with the Commission a Registration Statement covering the resale of all of the Registrable Securities not already covered by an existing and effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415 or, if Rule 415 is not available for offers and sales of the Registrable Securities, by such other means of distribution of Registrable Securities as the Holders may reasonably specify (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Initial Registration Statement</font><font style="font-size:12pt;">&#8221;). The Initial Registration Statement shall be on Form S-3 (or such other form available to register for resale the Registrable Securities as a secondary offering) and shall contain (except if otherwise required pursuant to written comments received from the Commission upon a review of such Registration Statement) a &#8220;Plan of Distribution&#8221; section substantially in the form attached hereto as </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex A</u><font style="font-size:12pt;"> (which may be modified to respond to comments, if any, provided by the Commission). Notwithstanding the registration obligations set forth in this </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2</u><font style="font-size:12pt;">, in the event the Commission informs the Company that all of the Registrable Securities cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a single registration statement, the Company agrees to promptly (i) inform each of the Holders thereof and use its</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">4</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">commercially reasonable efforts to file amendments to the Initial Registration Statement as required by the Commission, and/or (ii) withdraw the Initial Registration Statement and file a new registration statement (a &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">New Registration Statement</font><font style="font-size:12pt;">&#8221;), in either case covering the maximum number of Registrable Securities permitted to be registered by the Commission, on Form S-3 or such other form available to register for resale the Registrable Securities as a secondary offering. Notwithstanding any other provision of this Agreement, if any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered on a particular Registration Statement as a secondary offering, unless otherwise directed in writing by a Holder as to its Registrable Securities, any such limitation imposed pursuant to this </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2(a)</u><font style="font-size:12pt;"> shall be allocated among the Registrable Securities of the Holders on a pro rata basis, subject to a determination by the Commission that certain Holders must be reduced first based on the number of Registrable Securities held by such Holders. In the event the Company amends the Initial Registration Statement or files a New Registration Statement, as the case may be, under clauses (i) or (ii) above, the Company will use its commercially reasonable efforts to file with the Commission, as promptly as allowed by the Commission or SEC Guidance provided to the Company or to registrants of securities in general, one or more registration statements on Form S-3 or such other form available to register for resale those Registrable Securities that were not registered for resale on the Initial Registration Statement, as amended, or the New Registration Statement (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Remainder Registration Statements</font><font style="font-size:12pt;">&#8221;). No Holder shall be named as an &#8220;underwriter&#8221; in any Registration Statement without such Holder&#8217;s prior written consent.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">The Company shall use its commercially reasonable efforts to cause each Registration Statement or any post-effective amendment thereto to be declared effective by the Commission as soon as practicable and, with respect to the Initial Registration Statement or the New Registration Statement, as applicable, no later than the Effectiveness Deadline, and shall use its commercially reasonable efforts to keep each Registration Statement continuously effective under the Securities Act until the earliest of (i) such time as all of the Registrable Securities covered by such Registration Statement have been publicly sold by the Holders; (ii) such time as all Registrable Securities covered by such Registration Statement may be sold (A) without limitations as to volume of sales, method of sale requirements or notice requirements pursuant to Rule 144 and (B) without the requirement for the Company to be in compliance with the current public information requirement under Rule 144(c)(1); or (iii) the date that is one year following the Closing Date (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Effectiveness Period</font><font style="font-size:12pt;">&#8221;). The Company shall, by 5:00 p.m. New York City time on the first Trading Day after the Effective Date, file a final Prospectus with the Commission, as required by Rule 424(b).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">Each Holder agrees to furnish to the Company a completed Selling Stockholder Questionnaire not more than ten Trading Days following the date of this Agreement. At least ten Trading Days prior to the first anticipated filing date of a Registration Statement for any registration under this Agreement, the Company will notify each Holder of the information the Company requires from that Holder other than the information contained in the Selling Stockholder Questionnaire, if any, which shall be completed and delivered to the Company promptly upon request and, in any event, within three Trading Days prior to the applicable anticipated filing date. &#160;Each Holder further agrees that it shall not be entitled to be named as a selling security holder in the Registration Statement or use the Prospectus for offers and resales of Registrable Securities at any time, unless such Holder has returned to the Company a</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">5</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">completed and signed Selling Stockholder Questionnaire and a response to any requests for further information as described in the previous sentence. &#160;Each Holder acknowledges and agrees that the information in the Selling Stockholder Questionnaire or request for further information as described in this </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2(c)</u><font style="font-size:12pt;"> will be used by the Company in the preparation of the Registration Statement and hereby consents to the inclusion of such information in the Registration Statement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">3.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registration Procedures</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">In connection with the Company&#8217;s registration obligations hereunder, the Company shall:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;"> (i) Subject to </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3(g)</u><font style="font-size:12pt;">, prepare and file with the Commission such amendments (including post-effective amendments) and supplements to each Registration Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement continuously effective as to the applicable Registrable Securities for its Effectiveness Period; (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented or amended, to be filed pursuant to Rule 424; (iii) respond as promptly as reasonably practicable to any comments received from the Commission with respect to each Registration Statement or any amendment thereto; and (iv) comply with the provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by a Registration Statement until such time as all of such Registrable Securities cease to be Registrable Securities or shall have been disposed of (subject to the terms of this Agreement) in accordance with the intended methods of disposition by the Holders thereof as set forth in such Registration Statement as so amended or in such Prospectus as so supplemented;</font><i style="font-size:12pt;font-style:italic;"> provided, however,</i><font style="font-size:12pt;"> that in the event the Company informs the Holders in writing that it does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Holders are required to deliver a Prospectus in connection with any disposition of Registrable Securities, each such Holder shall be responsible for the delivery of the Prospectus to the Persons to whom such Holder sells any of the Registrable Securities, and each Holder agrees to dispose of Registrable Securities in compliance with the &#8220;Plan of Distribution&#8221; described in the Registration Statement and otherwise in compliance with applicable federal and state securities laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">Notify the Holders (which notice shall be accompanied by an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as reasonably practicable via facsimile or electronic mail: (i) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of a Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings for that purpose; (ii) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such purpose; and (iii) of the occurrence of any event or passage of time that makes the financial statements included in a Registration Statement ineligible for inclusion therein or any statement made in such Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to such Registration Statement, Prospectus or other documents so that, in the case of such Registration Statement or the Prospectus, as the case may be, it will not</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">6</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus, form of prospectus or amendment or supplement thereto, in light of the circumstances under which they were made), not misleading.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">Use commercially reasonable efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, as soon as reasonably practicable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:12pt;">If requested by a Holder, furnish to such Holder, without charge, at least one conformed copy of each Registration Statement and each amendment thereto and all exhibits to the extent requested by such Person (including those previously furnished or incorporated by reference) promptly after the filing of such documents with the Commission;</font><i style="font-size:12pt;font-style:italic;"> provided</i><font style="font-size:12pt;">, that the Company shall have no obligation to provide any document pursuant to this clause that is available on the Commission&#8217;s EDGAR system.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(e)</font></font><font style="font-size:12pt;">Prior to any resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify or cooperate with the selling Holders in connection with the registration or qualification (or exemption from the registration or qualification) of such Registrable Securities for resale by the Holder under the securities or &#8220;blue sky&#8221; laws of such jurisdictions within the United States as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions of the Registrable Securities covered by each Registration Statement; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction where it is not then so subject, or file a general consent to service of process in any such jurisdiction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(f)</font></font><font style="font-size:12pt;">If requested by a Holder, cooperate with such Holder to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be delivered to a transferee pursuant to the Registration Statement, which certificates shall be free, to the extent permitted by the applicable Subscription Agreement and under law, of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered in such names as any such Holders may reasonably request.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(g)</font></font><font style="font-size:12pt;">Following the occurrence of any event contemplated by </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3(b)</u><font style="font-size:12pt;">, as promptly as reasonably practicable (taking into account the Company&#8217;s good faith assessment of any adverse consequences to the Company and its stockholders of the premature disclosure of such event), prepare a supplement or amendment, including a post-effective amendment, to the affected Registration Statements or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document so that, as thereafter delivered, no Registration Statement nor any Prospectus will contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus, form of prospectus or amendment or supplement thereto, in light of the circumstances under which they were made), not misleading. If the Company notifies the Holders in accordance with </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3(b)</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">7</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">above to suspend the use of any Prospectus until the requisite changes to such Prospectus have been made, then the Holders shall suspend use of such Prospectus. The Company will use its commercially reasonable efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. &#160;The Company shall be entitled to exercise its right under this </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3(g)</u><font style="font-size:12pt;"> to suspend the availability of a Registration Statement and Prospectus for a period not to exceed 45 calendar days (which need not be consecutive days) in any 12-month period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(h)</font></font><font style="font-size:12pt;">The Company may require each selling Holder to furnish to the Company a certified statement as to (i) the number of shares of Common Stock beneficially owned by such Holder and any Affiliate thereof, (ii) any Financial Industry Regulatory Authority, Inc. (&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">FINRA</font><font style="font-size:12pt;">&#8221;) affiliations, (iii) any natural persons who have the power to vote or dispose of the common stock, and (iv) any other information as may be requested by the Commission, FINRA or any state securities commission.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(i)</font></font><font style="font-size:12pt;">In the event the number of shares available under any Registration Statement is insufficient to cover all of the Registrable Securities required to be covered by such Registration Statement, the Company shall amend such Registration Statement (if permissible), or file with the Commission a new registration statement, so as to cover at least all Registrable Securities immediately preceding the date of the filing of such amendment or new registration statement, in each case, as soon as practicable, but in any event not later than fifteen (15) Trading Days after the necessity therefor arises. The Company shall use its commercially reasonable efforts to cause such amendment to such registration statement to become effective as soon as practicable following the filing thereof with the Commission, but in no event later than the applicable Effectiveness Deadline for such registration statement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">4.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registration Expenses</u><font style="font-size:12pt;">. All fees and expenses incident to the Company&#8217;s performance of or compliance with its obligations under this Agreement (excluding any underwriting discounts and selling commissions and all legal fees and expenses of legal counsel for any Holder) shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. In addition, the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required hereunder. In no event shall the Company be responsible for any underwriting, broker or similar fees or commissions of any Holder or any legal fees or other costs of the Holders. Expenses of any Registration Statement abandoned prior to the effectiveness thereof at the request of the Holders shall be borne by the Holders.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">5.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification by the Company</u><font style="font-size:12pt;">. The Company shall, notwithstanding any termination of this Agreement, indemnify, defend and hold harmless each Holder, the officers, directors, agents and employees of each of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, agents and employees of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">8</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">costs (including, without limitation, reasonable costs of preparation and reasonable attorneys&#8217; fees) and expenses (collectively, &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Losses</font><font style="font-size:12pt;">&#8221;), as incurred, that arise out of or are based upon any untrue or alleged untrue statement of a material fact contained in any Registration Statement, Prospectus, form of prospectus or amendment or supplement thereto (it being understood that the Holder has approved </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex A</u><font style="font-size:12pt;"> hereto for this purpose), or arising out of or relating to any omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus, form of prospectus or amendment or supplement thereto, in light of the circumstances under which they were made) not misleading, except to the extent, but only to the extent that (A) such untrue statements, alleged untrue statements, omissions or alleged omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder, or to the extent that such information relates to such Holder or such Holder&#8217;s proposed method of distribution of Registrable Securities and was reviewed and approved in writing by such Holder expressly for use in the Registration Statement, Prospectus, form of prospectus or in any amendment or supplement thereto (it being understood that each Holder has approved </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex A</u><font style="font-size:12pt;"> hereto for this purpose) or (B) in the case of an occurrence of an event of the type specified in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3(b)</u><font style="font-size:12pt;">, related to the use by a Holder of an outdated or defective Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated or defective and prior to the receipt by such Holder of the Advice contemplated and defined in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6(c)</u><font style="font-size:12pt;"> below, or (C) any such Losses arise out of the Holder&#8217;s (or any other indemnified Person&#8217;s) failure to send or give a copy of the Prospectus or supplement (as then amended or supplemented), if required pursuant to Rule 172 under the Securities Act (or any successor rule), to the Persons asserting an untrue statement or alleged untrue statement or omission or alleged omission at or prior to the written confirmation of the sale of Registrable Securities to such Person, if such statement or omission was corrected in such Prospectus or supplement. The Company shall notify the Holders promptly of the institution, threat or assertion of any Proceeding arising from or in connection with the transactions contemplated by this Agreement of which the Company is aware.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification by Holders</u><font style="font-size:12pt;">. Each Holder shall, severally and not jointly, and notwithstanding any termination of this Agreement, indemnify and hold harmless the Company, its directors, officers, agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, agents or employees of such controlling Persons, to the fullest extent permitted by applicable law, from and against all Losses, as incurred, arising out of or are based solely upon (i) such Holder&#8217;s failure to comply with the prospectus delivery requirements of the Securities Act, or (ii) any untrue or alleged untrue statement of a material fact contained in any Registration Statement, Prospectus, form of prospectus or amendment or supplement thereto, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus, form of prospectus or amendment or supplement thereto, in light of the circumstances under which they were made) not misleading to the extent, but only to the extent, that (A) such untrue statements or omissions are based upon information regarding such Holder furnished in writing to the Company by such Holder expressly for use therein or (B) such information relates to such Holder and was reviewed and approved in writing by such Holder expressly for use in any Registration Statement, Prospectus, form of prospectus or amendment or supplement thereto (it being understood that the Holder has approved </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex A</u><font style="font-size:12pt;"> hereto for this purpose), or (C) in the case of an occurrence of an event of the type specified in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3(b)</u><font style="font-size:12pt;">, such Losses are related to</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">9</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">the use by such Holder of an outdated or defective Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated or defective and prior to the receipt by such Holder of the Advice contemplated in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6(c)</u><font style="font-size:12pt;">. In no event shall the liability of any selling Holder hereunder be greater in amount than the dollar amount of the net proceeds received by such Holder upon the sale of the Registrable Securities giving rise to such indemnification obligation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conduct of Indemnification Proceedings</u><font style="font-size:12pt;">. If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Indemnified Party</font><font style="font-size:12pt;">&#8221;), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Indemnifying Party</font><font style="font-size:12pt;">&#8221;) in writing, and the Indemnifying Party shall have the right to assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all reasonable fees and expenses incurred in connection with the defense thereof;</font><i style="font-size:12pt;font-style:italic;"> provided</i><font style="font-size:12pt;">, that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have materially and adversely prejudiced the Indemnifying Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (i) the Indemnifying Party has agreed in writing to pay such fees and expenses; (ii) the Indemnifying Party shall have failed promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; or (iii) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and such Indemnified Party shall have been advised by counsel that a conflict of interest would exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof and such counsel shall be at the expense of the Indemnifying Party);</font><i style="font-size:12pt;font-style:italic;"> provided</i><font style="font-size:12pt;">, that the Indemnifying Party shall not be liable for the fees and expenses of more than one separate firm of attorneys at any time for all Indemnified Parties. The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its prior written consent, which consent shall not be unreasonably withheld, delayed or conditioned. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding and such settlement does not include any non-monetary limitation on the actions of any Indemnified Party or any of its affiliates or any admission of fault or liability on behalf of any such Indemnified Party.</font><font style="font-size:12pt;"> &#160;Notwithstanding any other provision of this </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5(c)</u><font style="font-size:12pt;">, if an Indemnified Party withholds its consent to a bona fide settlement offer, where but for such action the Indemnifying Party could have settled a Proceeding, the Indemnifying Party will be required to indemnify the Indemnified Party only up to the amount of the bona fide settlement offer for which the Indemnifying Party could have settled such Proceeding.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">10</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Subject to the terms of this Agreement, all fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5</u><font style="font-size:12pt;">) shall be paid to the Indemnified Party, as incurred, within 20 </font><font style="font-size:12pt;">Business</font><font style="font-size:12pt;"> Days of written notice thereof to the Indemnifying Party;</font><i style="font-size:12pt;font-style:italic;"> provided</i><font style="font-size:12pt;">, that the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such actions for which such Indemnified Party is finally judicially determined to not be entitled to indemnification hereunder. The failure to deliver written notice to the Indemnifying Party within a reasonable time of the commencement of any such action shall not relieve such Indemnifying Party of any liability to the Indemnified Party under this </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5</u><font style="font-size:12pt;">, except to the extent that the Indemnifying Party is materially and adversely prejudiced in its ability to defend such action.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contribution</u><font style="font-size:12pt;">. If a claim for indemnification under </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5(a)</u><font style="font-size:12pt;"> or </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5(b)</u><font style="font-size:12pt;"> is unavailable to an Indemnified Party (by reason of public policy or otherwise), then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result of such Losses, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement, any reasonable attorneys&#8217; or other reasonable fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5</u><font style="font-size:12pt;"> was available to such party in accordance with its terms.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The parties hereto agree that it would not be just and equitable if contribution pursuant to this </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5(d)</u><font style="font-size:12pt;"> were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph. Notwithstanding the provisions of this </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5(d)</u><font style="font-size:12pt;">, (A) no Holder shall be required to contribute, in the aggregate, any amount in excess of the amount by which the net proceeds actually received by such Holder from the sale of the Registrable Securities subject to the Proceeding exceeds the amount of any damages that such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission and (B) no contribution will be made under circumstances where the maker of such contribution would not have been required to indemnify the Indemnified Party under the fault standards set forth in this </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5</u><font style="font-size:12pt;">. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The indemnity and contribution agreements contained in this </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5</u><font style="font-size:12pt;"> are in addition to any liability that the Indemnifying Parties may have to the Indemnified Parties and are not in diminution or limitation of the indemnification provisions under </font><font style="font-size:12pt;">any Subscription</font><font style="font-size:12pt;"> Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">11</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">6.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remedies</u><font style="font-size:12pt;">. Subject to the limitations set forth elsewhere in this Agreement, in the event of a breach by the Company or by a Holder of any of their obligations under this Agreement, each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery of damages, will be entitled to specific performance of its rights under this Agreement. The Company and each Holder agree that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the provisions of this Agreement and hereby further agree that, in the event of any action for specific performance in respect of such breach, it shall waive the defense that a remedy at law would be adequate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance</u><font style="font-size:12pt;">. Each Holder covenants and agrees that it will comply with the prospectus delivery requirements of the Securities Act as applicable to it (unless an exemption therefrom is available) in connection with sales of Registrable Securities pursuant to the Registration Statement, and shall sell the Registrable Securities only in accordance with a method of distribution described in the Registration Statement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Discontinued Disposition</u><font style="font-size:12pt;">. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice from the Company of the occurrence of any event of the kind described in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3(b)</u><font style="font-size:12pt;">, such Holder will forthwith discontinue disposition of such Registrable Securities under a Registration Statement until it is advised in writing (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Advice</font><font style="font-size:12pt;">&#8221;) by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed. The Company will use its commercially reasonable efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The Company may provide appropriate stop orders to enforce the provisions of this paragraph.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendments and Waivers</u><font style="font-size:12pt;">. The provisions of this Agreement, including the provisions of this </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6(d)</u><font style="font-size:12pt;">, may not be amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing and signed by the Company and the Holders of no less than a majority in interest of the then outstanding Registrable Securities, and any amendment to any provision of this Agreement made in accordance with this </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6(d)</u><font style="font-size:12pt;"> shall be binding on all Holders. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of certain Holders and that does not directly or indirectly affect the rights of other Holders may be given by Holders of at least a majority of the Registrable Securities to which such waiver or consent relates; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, that no amendment or waiver to any provision of this Agreement relating to naming any Holder or requiring the naming of any Holder as an underwriter may be effected in any manner without such Holder&#8217;s prior written consent. </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2(a)</u><font style="font-size:12pt;"> may not be amended or waived except by the written consent of each Holder affected by such amendment or waiver.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u><font style="font-size:12pt;">. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be delivered as set forth in the applicable Subscription Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">12</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</u><font style="font-size:12pt;">. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties and shall inure to the benefit of each Holder. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. The Company may not assign its rights (except by merger or in connection with another entity acquiring all or substantially all of the Company&#8217;s assets) or obligations hereunder without the prior written consent of the Holders of a majority of the then outstanding Registrable Securities. Each Holder may assign its respective rights with respect to any or all of its Shares hereunder in the manner and to the Persons as permitted under such Holder&#8217;s Subscription Agreement; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> in each case that (i) the Holder agrees in writing with the transferee or assignee to assign such rights and related obligations under this Agreement, and for the transferee or assignee to assume such obligations, and a copy of such agreement is furnished to the Company within a reasonable time after such assignment, (ii) the Company is, within a reasonable time after such transfer or assignment, furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being transferred or assigned, (iii) at or before the time the Company received the written notice contemplated by clause (ii) of this sentence, the transferee or assignee agrees in writing with the Company to be bound by all of the provisions contained herein, and (iv) the transferee is an &#8220;accredited investor,&#8221; as that term is defined in Rule 501 of Regulation D.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Execution and Counterparts</u><font style="font-size:12pt;">. This Agreement may be executed in two or more counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same Agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a &#8220;.pdf&#8221; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &#8220;.pdf&#8221; signature were the original thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(h)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u><font style="font-size:12pt;">. This Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware for contracts to be wholly performed in such state and without giving effect to the principles thereof regarding the conflict of laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(i)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cumulative Remedies</u><font style="font-size:12pt;">. Except as provided herein, the remedies provided herein are cumulative and not exclusive of any other remedies provided by law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(j)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u><font style="font-size:12pt;">. If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(k)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Construction</u><font style="font-size:12pt;">. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">13</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Any references to paragraphs, subparagraphs, sections or subsections are to those parts of this Agreement, unless the context clearly indicates to the contrary. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. This Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">14</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">COMPANY</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b><font style="font-size:12pt;">,</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">a Delaware corporation</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:44.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Linda Marb</font><font style="font-size:12pt;">&#225;n, Ph.D.</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:bottom;width:44.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Linda Marb&#225;n, Ph.D.</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Chief Executive Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[SIGNATURE PAGES&#160;OF HOLDERS&#160;FOLLOW]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">HOLDER:</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">AUTHORIZED SIGNATORY</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:44.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Takanori Edamitsu</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:bottom;width:44.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Takanori Edamitsu</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Director, Business Management &amp; Sustainability</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ANNEX A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">PLAN OF DISTRIBUTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The Selling Stockholders and any of their assignees and successors-in-interest may, from time to time, sell any or all of their shares of Common Stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. &#160;These sales may be at fixed or negotiated prices. &#160;The Selling Stockholders may use any one or more of the following methods when selling shares:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">an exchange distribution in accordance with the rules of the applicable exchange;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">privately negotiated transactions;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">broker-dealers may agree with the Selling Stockholders to sell a specified number of such shares at a stipulated price per share;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">a combination of any such methods of sale; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">any other method permitted pursuant to applicable law.</font></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The Selling Stockholders may also sell shares under Rule 144 under the Securities Act of 1933, as amended, if available, rather than under this prospectus.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Broker-dealers engaged by the Selling Stockholders may arrange for other broker-dealers to participate in sales. &#160;Broker-dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated. &#160;The Selling Stockholders do not expect these commissions and discounts to exceed what is customary in the types of transactions involved.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The Selling Stockholders and any broker-dealers or agents that are involved in selling the shares may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. &#160;In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">We are required to pay all fees and expenses incident to the registration of the shares, but not including certain fees and disbursements of counsel to the Selling Stockholders; in addition, a Selling Stockholder will pay all underwriting discounts and selling commissions, if any. We have agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. We may be indemnified by the Selling Stockholders against civil liabilities, including liabilities under the Securities Act, that may arise</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">A-</font><font style="font-size:12pt;">1</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">from any written information furnished to us by the Selling Stockholder specifically for use in this prospectus, in accordance with the registration rights agreement, or we may be entitled to contribution.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">To the extent required, we will amend or supplement this prospectus to disclose material arrangements regarding the plan of distribution.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">To comply with the securities laws of certain jurisdictions, registered or licensed brokers or dealers may need to offer or sell the shares offered by this prospectus. &#160;The applicable rules and regulations under the Securities Exchange Act of 1934, as amended, may limit any person engaged in a distribution of the shares of common stock covered by this prospectus in its ability to engage in market activities with respect to such shares. &#160;A Selling Stockholder, for example, will be subject to applicable provisions of the Exchange Act and the rules and regulations under it, including, without limitation, Regulation M of the Exchange Act, which provisions may limit the timing of purchases and sales of any shares of common stock by that Selling Stockholder. Regulation M may also restrict the ability of any person engaged in the distribution of the shares of common stock to engage in market-making activities with respect to the shares of common stock. All of the foregoing may affect the marketability of the shares of common stock and the ability of any person or entity to engage in market-making activities with respect to the shares of common stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">A-</font><font style="font-size:12pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ANNEX B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CAPRICOR THERAPEUTICS</b><b style="font-size:12pt;font-weight:bold;">, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">SELLING STOCKHOLDER NOTICE AND QUESTIONNAIRE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="font-size:12pt;">[See separate document.]</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">B-</font><font style="font-size:12pt;">1</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>capr-20240916xex10d3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 9/17/2024 12:49:24 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit&#160;10.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Letter of Intent</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">September 16, 2024</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CONFIDENTIAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Capricor Therapeutics, Inc.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Dear Dr. Linda Marb&#225;n:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">Nippon Shinyaku Co., Ltd., a corporation organized under the laws of Japan, with its principal office located at 14, Nishinosho-Monguchi-cho, Kisshoin, Minami-ku, Kyoto 601-8550, Japan (&#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">NS</font><font style="font-size:11pt;">&#8221;), is pleased to submit to Capricor Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with its principal office located at 10865 Road to the Cure, Ste. 150, San Diego, CA 92121 USA and its subsidiary Capricor, Inc. (collectively &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Capricor</font><font style="font-size:11pt;">&#8221;), this letter of intent (&#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Letter of Intent</font><font style="font-size:11pt;">&#8221;) regarding an exclusive right to distribute deramiocel (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Product</font><font style="font-size:11pt;">&#8221;) for the treatment of DMD in Europe, as detailed herein, for further collaboration between the parties in addition to US and Japan. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:bold;">1.</font></font><u style="font-size:11pt;font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term Sheet</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">This Letter of Intent and the term sheet attached hereto (&#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Term Sheet</font><font style="font-size:11pt;">&#8221;) shall be binding and shall provide the basis for a definitive agreement (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Agreement</font><font style="font-size:11pt;">&#8221;) to be executed between the parties in accordance with the Binding Schedule set forth in Article 3 below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:bold;">2.</font></font><u style="font-size:11pt;font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">NS shall make a payment to Capricor of 15 million U.S. dollars through a purchase of common shares of Capricor Therapeutics, Inc. wherein the purchase price shall be received by Capricor within four (4) days from the execution date of the share purchase agreement (&#8220;</font><b style="font-size:11pt;font-weight:bold;">SPA</b><font style="font-size:11pt;">&#8221;) to be entered into between NS and Capricor Therapeutics, Inc. The purchase price of the common shares of Capricor Therapeutics, Inc. shall be at a twenty percent (20%) premium based on the 60-day VWAP prior to the execution date of the SPA. &#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">In addition, NS shall make a payment to Capricor of 20 million U.S. dollars in cash within thirty (30) days from the date of the invoice to be issued by Capricor after the execution of the Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">Capricor and NS shall cooperate in good faith to apply for and obtain exemptions or reductions of any and all withholding taxes.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:bold;">3.</font></font><u style="font-size:11pt;font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Schedule</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">The Agreement shall be executed no later than September 30</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;">, 2024 (&#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Due Date</font><font style="font-size:11pt;">&#8221;). Capricor shall provide NS with the first draft of the Agreement within five (5) days after the execution of this Letter of Intent.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">Notwithstanding the foregoing, NS shall have the right to extend the Due Date for a period not to exceed ninety (90) days at its sole discretion at any time with notice to Capricor. &#160;In the event of any delay in the provision of such first draft of the Agreement by Capricor, the Due Date shall be further extended by the number of days of such delay.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">During the duration of this Letter of Intent, both parties shall engage in good faith negotiations based on the Term Sheet and Capricor shall not engage in any negotiations with any third party on the rights which conflict with those to be granted to NS under the Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:bold;">4.</font></font><u style="font-size:11pt;font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transaction Expenses</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">Each party shall be responsible for its own respective attorney fees, other professional fees and other transaction fees and expenses related to the matters contemplated herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:bold;">5.</font></font><u style="font-size:11pt;font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Duration</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">This Letter of Intent shall come into force on the signature date of Capricor below and shall continue to be effective in full force until the earlier of (i) execution of the Agreement, (ii) NS&#8217;s written notice to Capricor not to execute the Agreement, and (iii) expiration of the Due Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:bold;">6.</font></font><u style="font-size:11pt;font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">This Letter of Intent shall be governed by and construed under the laws of the State of New York without regard to its conflict of law provisions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:bold;">7.</font></font><u style="font-size:11pt;font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arbitration</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">All disputes, controversies or differences arising out of or in connection with this Letter of Intent shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce by three (3) arbitrators appointed in accordance with said Rules. The place of the arbitration shall be New York, New York or Los Angeles, California and shall be determined by the party that initiated the arbitration. The arbitral proceedings shall be conducted in English. The award of the arbitration shall be final and binding on the parties.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:bold;">8.</font></font><u style="font-size:11pt;font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Effect</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">The parties hereto acknowledge and agree that the agreements, covenants and obligations contained in this Letter of Intent are legally binding and enforceable in accordance with their terms. &#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">This Letter of Intent supersedes all prior agreements, discussions, understandings and negotiations, oral, electronic or written, between the parties regarding the subject matter hereof. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Very truly yours,</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Nippon Shinyaku Co., Ltd. </font></p></td></tr><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:bottom;width:43.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Toru Naki</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Name:</font></p></td><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Toru Nakai</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Title:</font></p></td><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">President</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Date:</font></p></td><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">September 16, 2024</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:59.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Accepted and agreed to as of the date below:</font></p></td></tr><tr><td style="vertical-align:bottom;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:59.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Capricor Therapeutics, Inc. (on behalf of itself and Capricor, Inc.) </font></p></td></tr><tr><td style="vertical-align:bottom;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:bottom;width:51.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Linda Marb&#225;n</font></p></td></tr><tr><td style="vertical-align:bottom;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Name:</font></p></td><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Linda Marb&#225;n</font></p></td></tr><tr><td style="vertical-align:bottom;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Title:</font></p></td><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">CEO</font></p></td></tr><tr><td style="vertical-align:bottom;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Date:</font></p></td><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">September 16, 2024</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>capr-20240916xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 9/17/2024 12:49:24 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="capr-20240916xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:45.6pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:121.2pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">-Capricor to Receive $15 Million Equity Investment at a 20% Premium, as well as $20 Million Upfront Payment upon Signing Definitive Agreement with up to $715 Million in Potential Milestones and a Double-Digit Percentage of Product Revenue-</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">-Upfront Payment and Investment Extends Cash Runway into 2026-</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">-Potential Milestones from Combined Distribution Agreements Now Total approximately $1.5 Billion- </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">-Capricor Preparing to Meet with EMA to Discuss European Expansion for Deramiocel-</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">SAN DIEGO, </b>Sept. 17, 2024 (GLOBE NEWSWIRE) -- <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capricor Therapeutics</u> (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced it has entered into a binding term sheet with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nippon Shinyaku Co., Ltd.</u>, a Japanese pharmaceutical company listed on the TYO, for the commercialization and distribution in Europe of Capricor&#8217;s lead asset, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD), a rare neuromuscular disease with limited treatment options. The potential transaction covered by the term sheet is similar to the existing Commercialization and Distribution Agreements with Nippon Shinyaku in the United States and Japan with an opportunity for further product reach globally. In addition, Nippon Shinyaku has agreed to purchase approximately $15 million of Capricor common stock at a 20% premium to the 60-day VWAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">Under the terms of the binding term sheet and further subject to finalization of a Definitive Agreement, which is expected to occur in the fourth quarter of 2024, Capricor will be responsible for the development and manufacturing of deramiocel for potential approval in all countries in the European Union, United Kingdom and several other countries in the region. Nippon Shinyaku will be responsible for the sales and distribution of deramiocel in those territories. Capricor will also receive an upfront payment of $20 million subject to execution of the Definitive Agreement and there are potential additional development and sales-based milestone payments to Capricor of up to $715 million and Capricor will receive a double-digit share of product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">&#8220;Our expanded partnership with Nippon Shinyaku into the European region marks a pivotal moment for Capricor as we work together to bring deramiocel to DMD patients worldwide,&#8221; said Linda Marb&#225;n, Ph.D., Capricor&#8217;s Chief Executive Officer. &#8220;With the addition of the upfront payment and equity investment, we will be able to extend our runway into 2026 and be well positioned to advance toward potential approval of deramiocel in the United States and beyond. Furthermore, these funds will provide necessary capital for commercial launch preparations, manufacturing scale-up and product development for Europe, as we envision high global demand for deramiocel.&#8221; &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">Dr. Marb&#225;n continued, &#8220;As previously reported, we held a successful pre-BLA meeting with the U.S. Food and Drug Administration (FDA) in August. Since that meeting, we have now had several additional informal meetings with the agency to continue to refine our approval pathway for deramiocel in the United States and we plan to provide further updates as they become available.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">Toru Nakai, President of Nippon Shinyaku, commented, &#8220;We look forward to building deramiocel&#8217;s commercial footprint around the world and this partnership would allow us to continue to invest in Nippon Shinyaku&#8217;s DMD franchise and to potentially advance life-changing therapies for patients in need.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">Contemporaneously with the term sheet, Nippon Shinyaku has also agreed to purchase 2,798,507 shares of common stock at a price of $5.36 per share, which price represents a 20% premium to the 60-day volume-weighted average price (VWAP) of Capricor&#8217;s common stock, for an aggregate purchase price of approximately $15 million. The closing of the offering is expected to take place on or about September 20, 2024. The Company expects to use the proceeds from the transaction primarily to support product development as well as general, administrative and corporate purposes.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="capr-20240916xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:45.6pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:121.2pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"> <font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company has agreed to file a registration statement with the Securities and Exchange Commission for purposes of registering the resale by the investors of the shares of common stock purchased by such investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offering of the securities under the resale registration statement will only be by means of a prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">About Deramiocel (CAP-1002)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">Deramiocel consists of allogeneic cardiosphere-derived cells (CDCs), a population of stromal cells that have been shown in preclinical and clinical studies to exert potent immunomodulatory, antifibrotic and regenerative actions in dystrophinopathy and heart failure. CDCs act by secreting extracellular vesicles known as exosomes, which target macrophages and alter their expression profile so that they adopt a healing, rather than a pro-inflammatory, phenotype. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to over 200 human subjects across several clinical trials. Deramiocel for the treatment of DMD has received <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Orphan Drug Designation</u> and the regulatory pathway for deramiocel is supported by RMAT (<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regenerative Medicine Advanced Therapy Designation</u>). In addition, if Capricor were to receive FDA marketing approval for deramiocel for the treatment of DMD, Capricor would be eligible to receive a Priority Review Voucher (PRV) based on its previous receipt of a rare pediatric disease designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">About Duchenne Muscular Dystrophy &#160; &#160; </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">Duchenne muscular dystrophy (DMD) is a devastating genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart and respiratory muscles with mortality at a median age of approximately 30 years. It is estimated that DMD occurs in approximately one in every 3,500 male births and that the patient population is estimated to be approximately 15,000-20,000 in the United States. DMD pathophysiology is driven by the impaired production of functional dystrophin, which normally functions as a structural protein in muscle. The reduction of functional dystrophin in muscle cells leads to significant cell damage and ultimately causes muscle cell death and fibrotic replacement. Treatment options are limited and there is no cure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">About Nippon Shinyaku</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">Based on Nippon Shinyaku&#8217;s business philosophy, &#8220;Helping people lead healthier, happier lives,&#8221; we aim to be an organization trusted by the community through creating unique medicines that will bring hope to patients and families suffering from illness. Please visit our website <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(https://www.nippon-shinyaku.co.jp/english/</u>) for products or detailed information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">About Capricor Therapeutics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX&#8482; platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">capricor.com</u>, and follow Capricor on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Facebook</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Instagram</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Twitter</u>.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="capr-20240916xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:45.6pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:121.2pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Cautionary Note Regarding Forward-Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor&#8217;s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; statements about our financial outlook; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; potential future agreements; scope, duration, validity and enforceability of intellectual property rights; future revenue streams and projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor&#8217;s management team&#8217;s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words &#8220;believes,&#8221; &#8220;plans,&#8221; &#8220;could,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor&#8217;s business is set forth in Capricor&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on March 11, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, as filed with the Securities and Exchange Commission on August 8, 2024. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><i style="font-style:italic;">Capricor has entered into an agreement for the exclusive commercialization and distribution of deramiocel (CAP-1002) for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: </i><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NS Pharma, Inc.</i><i style="font-style:italic;">), subject to regulatory approval. Deramiocel is an Investigational New Drug and is not approved for any indications. None of Capricor&#8217;s exosome-based candidates have been approved for clinical investigation.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">For more information, please contact:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Capricor Media Contact:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raquel Cona</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">KCSA Strategic Communications </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">rcona@kcsa.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">212.896.1204</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Capricor Company Contact:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AJ Bergmann, Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">abergmann@capricor.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">858.727.1755</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>capr-20240916xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 capr-20240916xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !< /,# 2(  A$! Q$!_\0
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MSO8YZ.,E[5QE9-M:?+>^WR+FF^*9['1_&,VCAY-0:[-Q &MW):$L 944@>8
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M+13$FCD.%=6/L<T^@ HHICS1H<-(JGT)Q0 ^BD!S2T %%-WJ&QN&?3-#2*I
M9@">@)ZT .HHHH ;)_JV^AKS?X!?\B7>_P#86N__ $97I+#<I'J,5XG\/_&V
MG_"W4M;\*^*9AI!^W37=E>7 *PW$4C;N&Z CT->C0A*K0J0@KO1V\E?_ #.&
MM.-.M3G-V6JO]W^1/^T'90/?^#9#& \^J);RLI(,D9&2C8ZCV->QPPI;Q)%$
MBQQH JHHP !V%>$^+/$]M\8_B#X8T?PTQU#3]*NQ?7NHQJ?)3 X4-W->\U>+
M4J=&C3GHTF[=KO0C#.,ZM6I#5-K7T6I\-?M/2S_%']I7PUX):1A81R11% ?[
MWS.?K@&OM?1-&M/#VDVFFV$*6]I;1K%'&@P  ,5\2_M%M)\,?VJ_#GBVX0C3
MY9(9C)CC;]Q_R!-?<%A?0:G907=M*LUO,@DCD0Y#*1D&HQ-_94[;6_$TH?'.
M^]RQ2!0"2 ,GJ:6BO..TXKXPP>+KGP'?IX(FCA\0$#R3(!R,\@$\ X[FOG2U
M_8X\?>*(1>^*?B;=Q:C(-S0VYDE5#Z9WJ/R%>]_'7XQV7P4\$R:U<0?;+J1Q
M#:VH./,D/J>P'4UX?X=\;?M*?$;3H]9T?3M&T?3+@;X%NEC4LO8@-EL>YQ7H
MT/:QA>+27=G%5]FYVDFWV1Y_>ZA\1?V1/B+I%MJ>OS:_X9OW S+(SQR)G###
M$E&'7@U]VZ?>QZC8V]U$<QS1K(OT(S7YZ?M20_%N/3/#S?$B32Y+7[1)]C.G
M[-P?"[L[0.V*^]/ 1)\$Z$3R?L<7_H(JL6KPA-VN[[$X=VG*"O;S/DO]NCQ;
MJ7A/XD^"KJQO+B%(;;SV@BF9$D*S9PP!YSC%/T#X&_%/]H:S3Q3XM\8W'ANQ
MO1YMGIT.XD1G[IV!E"C'3.3]*I_MV"W;XL> !=X^RF%1-NZ;//\ F_3-?:FG
MB(6%L(,>2(UV;>FW'%7*JZ-"FX+5WU)C352K/F>A\->,?!'Q4_90FM_$.E^)
MIO$?AP2!9TD9RJ^SQL3@'^\#7UY\)?B38_%?P+IWB*Q'EBX7;-"3DQ2#[RG_
M #T-4/CZEF_P>\5B^V>1]AD^_P!-V/E_7%>,_P#!/UK@_#;6@^[[.+X>7GIG
M;SC]*SF_;T'4DO>3^\TBO95>1/1HS/V]M>O]"M_"DME>W-I^^=G%O,T>_&.#
M@US/ASX9_%C]IW3XO$.J>)W\+^'Y%"V5LK/\Z 8W!%(R/=CS6S_P4)4/:>$E
M/0RR#^5?5G@NSAT_PAHMM;H(X8[.)511@ ;!6GM71P\'%:ZF?L_:5IJ3TT+>
M@::^C:)86$DOGO;0)$TI_C*@#-?(7[+^MZC??M.?$*VN;^ZN+:.6\V0RS,R+
MBX(& 3@<5]F5\3_LJ?\ )TWQ&_ZZWO\ Z4FL*&M.JWV-JNDZ:7<^R/$&NV?A
MC0[[5M0E$%E9PM/+(W0*HR:^*K'7OB?^U]XFOUT359/"O@^U?;YB.R #L#MY
M=R.<9 %?0/[7;7"_ 'Q/]FSDI&'V_P!S>N[]*R/V)TLU^!E@;7;YIN)?/(Z[
MLCK^%.C:E1=9*[O;T%4O4JJFWI:YY;KO[(/Q!\#:?)K'A'X@7NHZI;#S/LC%
MXC+CG"G>P)]B*^A/@%K?C77? 5M-XZTMM.U93L!? >51T9E'W37I-%8U,1*K
M&TTF^YK"C&G*\?N/F7]J+]H?6?">M67@7P2GF>);_:LDZ+N:+=PJ(/[Q]>U<
MCIW[&'CGQ+9KJ/B;XCW=OK$HWF&(R3",GL6WC]!6/H BE_;SN?[6QO664VWF
M=-_E';C\,U]P5U5*CPT8QI[M7;.>$%7E*4^CM8^'+#X@?$?]DWQ[I^A^,;]_
M$7A2];$=R[EP4R 61FY5ER,J?_KU]MV%]!J=C;W=M();>>-9(W'1E(R#7S3_
M ,% %LC\)=*:;;]M&JQ_9O[W^K?=CVQ_2O7?V?VN'^#/A(W6?.^PIG=UQV_2
MLZ]JE*-:UF]&72O"I*G>ZW/D?]H[XB>(/ _[31NM(N;F:2&.+R;(2MY;.5P/
MDS@\FO1_AM^SO\2M=\3Z1XU\9^,I(YUF6Z.E;G?"]=IY"K] #7&?%&RBU#]M
MS1X9D#QF6 E2/05]R 8%;UJKI4X**U:W,J5-5)R<GLQ:***\@]$*IZEHUAK$
M8CO[*WO$'19XPX'YU<HIIM.Z$TFK,JZ?I5EI,/E65I#:1?W((P@_2K5%%#;;
MNP225D>:_';X)Z9\;?"+:;=.+748,R65Z!DQ/Z'U4]Q7ROX<^)7Q>_97<Z#K
MWA]]=T")BL#/N:/;_P!,I5!P/8CCTK[RIDL23QE)$61#U5AD'\*ZJ6(Y(\DU
MS1,*E'F?-%V9\:W_ .W_ *IJ%J;?1/A_(NHM\JM/=M,JG_<6,$_F*[G]F6V^
M+VN^)M3\4^-KI['1+Y/DTRZCP[M_"8T_Y9J/4]?3O7T-;:%IMG+YMOI]K!)U
MWQP*I_,"KU5.O3Y7&G"U_F3&E/F4IRO;Y'@G[8GPHU;XG?#JW?0XFNM1TJX^
MU+:KUE7!# >^#G%><?#[]M.W\'>$[/0O$O@W6TU?3XA;C[)$I23;P,ABI4_@
M:^PJJRZ99SR^;+:022?WWC4G\\5,*\>3V=2-TMNA4J4N?G@[,_/#]HSQEX[^
M,5II7B/4/#EQH?AB.<PZ?:."TCL0"SGC)XQS@"OOOP&I3P5H:L""+.+(/;Y1
M6U);13*%DB1U'0,H(%/ "@ # '845:ZJ0C!1LD%.DX2<F[W/AW]OO3WU;XE>
M"+&-@DES:^2K-T!:; )_.M'P]^T=\1/V?[2/PKXZ\&W&MQV2B*UOXI#&9(QP
MN'VLKC'0\'UIG[;O_)9_AO\ [L?_ *4BOKGQ!JD>EZ:LLVD7&J6ZQEW\A8F"
M #J0[K^F:[N9>RIPE'FO?R_$Y.5^TG)2M8^*?&_Q5^(_[5\T/A?P[X8FT30Y
M'!N&9F8$9ZR2%5  ] /SKZ]^#_PRLOA)X#T_P]9MYK0KOGGQCS93]YO\^E;6
MDZPLFF2W(TBYTR"-/,5)A$-XQG@([?KBKVG:M;:G;P21R('EC63RBX+*",\C
M\:Y*U24H\D8VBOF=%*"4N:3NV?)W[?UE<7=OX2\B"2;;,^?+0MCIZ5]5^&05
M\.:4",$6L0(/^X*LWTEG&JF\:!5SA3.5 S[9J<R(D88LJIQ@YXK&=1RIQA;:
MYK&"C.4K[CZ^+OV6K&Y@_:A^(DLMO+'$TM[M=T(!_P!)/0U]F"YA,)F$J>4.
MLFX;1^-1VGV28&>V\EPW62+!S^(HIU'3C*-M] G!3E%WV*OB7P]9^+- U#1]
M0C$UE>PM!*A[JPQ7Q-IDGQ'_ &,_$M_;1:/)XE\&W4N^-T#;&'8[@#L?'!R,
M&ON;[;;^:L?GQ>8W1-XR?PHNI8(H&-R\:0]"92 OZU5*JZ:<6KI]":E-3]Y.
MS74^-_$/[<'B3Q;8-I7@[P+>6NKW(\M9Y9#.R$_W55!S[D_A7T+\ [+QQ9^
M;8^/;L7&L2'>J%1YD2'HKD=37>VEI80+Y]K#;1J1GS(44 CZBK)E0!277YCA
M>>OTHJ582CR0A;\6$(23YIRN?+_[4WP!U[6=?LOB%X%5G\0V!5Y[6(XDDV_=
M=/4CH5[^]<MI'[=VO:'8BQ\2> +F;6(1L>2&9H [#U1HR0?H:^OVUBR34?L#
M7,:WFP2>46P<$X'\JCFM;6[U)HYM/BE*QAQ<2*C<DD8Q][MUQCFM8UER*%6%
M[;="'3]YRIRM??J?$=GX;^(7[8OC[3M4U_37\/\ @VP;*AU98U7()5-W+NV
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>capr-20240916.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/17/2024 12:49:30 AM-->
<!--Modified on: 9/17/2024 12:49:30 AM-->
<xsd:schema targetNamespace="http://capricor.com/20240916" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:capr="http://capricor.com/20240916" xmlns:rxp="http://xbrl.sec.gov/rxp/2024" xmlns:snj="http://xbrl.sec.gov/snj/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://capricor.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="capr-20240916_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="capr-20240916_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>capr-20240916_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/17/2024 12:49:30 AM-->
<!--Modified on: 9/17/2024 12:49:30 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>capr-20240916_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/17/2024 12:49:30 AM-->
<!--Modified on: 9/17/2024 12:49:30 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="capr-20240916.xsd#DocumentDocumentAndEntityInformation" roleURI="http://capricor.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://capricor.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638621309708222984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638621309708222984" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638621309708222984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638621309708222984" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638621309708222984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638621309708222984" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638621309708222984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638621309708222984" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638621309708222984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638621309708222984" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638621309708232993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638621309708232993" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638621309708232993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638621309708232993" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638621309708232993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638621309708232993" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638621309708232993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638621309708232993" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638621309708232993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638621309708232993" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638621309708232993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638621309708232993" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638621309708232993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638621309708232993" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638621309708232993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638621309708232993" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638621309708232993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638621309708232993" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638621309708232993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638621309708232993" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638621309708232993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638621309708232993" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638621309708242988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638621309708242988" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638621309708242988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638621309708242988" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638621309708242988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638621309708242988" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638621309708242988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638621309708242988" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638621309708242988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638621309708242988" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638621309708242988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638621309708242988" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641227040784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 16, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 16,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CAPRICOR THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">88-0363465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10865 Road to the Cure, Suite 150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">727-1755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CAPR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001133869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%
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M 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .1),5E40/-G\    "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( .1)
M,5F97)PC$ 8  )PG   3              "  <X!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ Y$DQ6=&-?AYA!   QA   !@
M ("!#P@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( .1)
M,5F?H!OPL0(  .(,   -              "  :8,  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ Y$DQ69>*NQS     $P(   L              ( !@@\
M %]R96QS+RYR96QS4$L! A0#%     @ Y$DQ61PX9>H_ 0  / (   \
M         ( !:Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( .1),5DD
M'INBK0   /@!   :              "  =<1  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( .1),5EED'F2&0$  ,\#   3
M      "  ;P2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(
'  84      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="capr-20240916x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>capr-20240916.xsd</File>
    <File>capr-20240916_lab.xml</File>
    <File>capr-20240916_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="capr-20240916x8k.htm">capr-20240916x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "capr-20240916x8k.htm": {
   "nsprefix": "capr",
   "nsuri": "http://capricor.com/20240916",
   "dts": {
    "schema": {
     "local": [
      "capr-20240916.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "capr-20240916_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "capr-20240916_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "capr-20240916x8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://capricor.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20240916x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20240916x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001558370-24-012836-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-012836-xbrl.zip
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M[I#9-P;H0.PBF1\-Q?YQ^SLRH_E29SV4AM:*.)9$5H-HRGHB@IDM)+X@C!N
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M)J=03F;DPR"9S3\IAYB9#"\$$P17WA(NZ7F9!:>A!9B(SSO].IJ IT#/C,$
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M*(D:*-?0O40HQ!+F MX!J#A,1+1-DTMJE7NO?>Q,Q%?"QA@]#RUCI"LNS$/
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MK.&3XHY!G#OX@(<BT^G9WO,'JM3?]=%XDZLB1J7E+6WDNG>2SP@2=6@&BLU
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MJ&XN84\:75A#%<S0=IZ"#M-?'KBI>7^532_\ $X#-?O!9<C<NM>!Q3%X>8G
ME[@:D%82@$,G!GD&@#\EVSMT&Q;] [V7F#?B!'?MWD*@CY[L>:;GP7M%=Q9I
M=GOYHM?G7CSVY LNL[M1J: 7LB!7C@-XHY*9"LR6<I+,0)LNZI(B'.81EB1U
MUOA$E:1+\>]_RX&7!JBLUEAEDX*BB\^8<,6<W/E4G,-/<N&._7",S7 R!G @
MF1(HJSB5]1"G3?4DQ(SST;8GE[)*@@PHB+[ $A_Y^9@H$,Z1KEGC/2ERM"+O
MZG9F?19:D_I%'FF-6M#-;B@'JT*4_<DT!#(G= \Q.T,"7QPT,V_9;&J+MV[_
M.?ZOC0UQ)>VO_.5*.W&*@5#4=0<SM)Z6Y*BM,L-ODE=ZPR_$=]TB+/[>?_;L
M&S:&+XX9J OCRD.O:AONS4KST):NTW!B)QC@,6-(@0F%@S/V(&P2C07_M2$-
MX^+!U'\O;H7O=Y6C*LYGW7.$,X8G"V0>6@D51]4)U11F@BN8Y24#)THR@C_I
M_JC='.-MK0.W&EK=QM2!].&K/GS5AZ\>>_CJN_+?I<BW:_-=P>=MX>(RHC#+
M:?@7@<*UDYN;\K_EB^QEY_*]RXLJ.%/I+6P@JM$RV9*&+7%8\XP2WR;[/TD-
M.]C;:\&JGOWZR4,+:M1B;@WK2G1U]*LV_, <N],2)V.TVR=P*(#]%9SYU7VP
M>OU]I58(P6"*3O1O/2"D/BV@@3?R:D&[(G<]/#5$B/^$D2&9PUAT\#BP"A6I
MR#,=,4C+4*?Y):O,Y@62.EL&&>K8W5T$.L,7J-!EL'%FQA.M*  B5.^@3VA6
M"^>[&<R-\Q3,!E82X<MD2LA<',F[4&!2($<;P8+*!W$@GX[P?]_A0%+^1&=7
M"1G_^0'^;^DYO,$)%MYVQ2\/?L+_+?Z2#$8[:3QD-WB]'P6\R1S@=NCJ)B^&
M:X=YV7Q?SHX.;_+V4XU!ZZL$R[+]"F]&\)@%Q!6_?:'Q?[?TPDN*'JK9#(XL
M7N'[>J]*R_PF>VK$Y T/,\/+!?D-]K.XV73EC3>8;_/B->H/<L1%O/U5+*5<
M)+[*5LR<@QV;S>_7X? WX>GG!<O4#Y1P?$.(S(4L?R_?W*0FERCY&[EYOG$1
MI$DI8;#?ZYQ<@)BI(Y,3G8$V#?CA[P)6^XH^_?BOLR,0_YK2UEB9^:C*6/T>
M'$HR-:^M\=4OG'RV_)LSC77 S0=@__^5%U]DTD8U#H-/YX?_>(-3QW_\7XFP
MH>2)(ETBTBLJ, TZ@:J5P\(V7/F]A[.W6#]T=Q6 K*WVP+@-\H^ )(/QS0JM
MCX"M8J),<(X!;8</^?[](=\8Z5N ]YC?A%'G:@%/TF!&V@MS]0^^'[92QR8]
M0#CX@PV @V^V^;NN>FVS[^D#/ + ^UIGX$KZGS>:AV!W!A)IPWKN8C VV=Y^
M3:W'R-ZF;F0+;@?7$TR<"R.3FF)<$;87V0R$.SD)_OQ\]^F+N^F3LYJW91E+
MW'!9\A#/Z'#M,THUS=KOA&)/$%FF*K45J6=WUX9."IW7.CVBR6#:;  ;!8==
MDG1S:BG.L"5)G.IY,,"CD(&0/0G9VXJ&#48=]_:YM_('+(\]S54<!F_J)"4-
M&K]*\V"05GD(>G&:P%W+$A6\?/9T[QD'UR6;MEGNL%5N<Y1]FI.O;#C'=%L*
MPFN6TB:R[C+&4'$N\BR)C(7 @849M\"DR#\WJ$F%6X2HX#M0EH,] \I"V6EV
M3J3^-W\9<Y\TB?-+D\W=8%#Y%><AIOC^Y4_[+T!F^8R,23Y3_...^X_C7H+A
MZ-013!I?[CFTE>XN9YRF/U39%YL&C:3F?Q)E>!+D2F>7:"-MP98O8>6H6X+Y
MAG\<486S=ZC9=2NMYE@+[L"OX=H*>F;>NA4\P%3%."QW-ACF^1=,!N3ZX%$"
ME]0UI?/F9)V]3>VRU]F^C1D^W0"=[53/X' @A"WG5^"Y_*<J$/<HT6WDBQ64
M.K2@X=('XB%=<'>*[S(T8/%TV'^OD7G-R5XH&A.R'(A2_>GPFK)GC%L1YE+,
MD2ETI)41<(<:3WOI_!Y]3DB?$]+GA/0Y(3<4+ L\CGF:"Z=+!+,T*N=I4GX)
MWBGJ&&-CE\#'''NB"C)XJL4CD8?)&/#9I2KBG10D-,79,>!)KC0S((VF8,U<
M(>GS/AF*%2SW2ZZNHE[IG&\)R@ZH&53]R$64,X2LX*YJ, :'<IO=_:29WQ3K
MBEONX:)#DEPZ2=+25^X?I>7'@RM/\P/4'Q8-_N_D]#'U]ZOH!P.0]Z)52!B*
MH_?R1^F7\[=QM_#H7J%4K*Y\^*/FEYA"T=T#+*3D&YF&@7&1_CG6-&+P,(/?
M0K/6"G0;%UD'A5JSM4J\SQ3>$*"A>$K=:R0IB\I9ZPHSFN-FIDUK'HMO0SI=
MP*F-$5S,C88?CVJJ:54)V)$9["5"I)4E63O4+A3G"2-Z$(=D8YO\;&[C2B;0
MD//XN<-HX6QRU_GGNY@'^'\_'ES+Q7TU8&]UC:5G5+?D]?D.C.I3,599\F]E
MLY#^059'PCZ155C7><M^IWMGC&R?;R54ER15=G&-U[!5%NALFIRGA9GOYL[J
MKTEIF\L#^Z+6O981.,6#JOKE_;_!I2MCQAZ5,GCOI<:2\DC@.0P*9&&@>>E@
MEE]B? :915U-<D)'A=L.+)(^1)<$#NQ %OE9PEEDIW$.[*E ;2*C)PT0"[)D
MU_!:8%ITO MG+3$5XY:VF<1:/9:6D%9SD>22T(B/Q'JDZK0RW-0X!Q'VH32P
MC3@'KU=LA+.F+:<Z$W0M12ESU0:Q$#J8J6NXO$\Z*04%AHR9![$)<H+X\0Y$
M&VBX?4#H6+#AF]BJ^P9XC;C9%T\ 84R.I(-#>XO] D_X)9W1QN%HH.E(NI[,
MV;[9;I!4SC%F-AP#=F0EE6B Y G[W;]'0:8QW =[AM ()(TYG8?!"1AP@%U1
M9>ZMGS$(&^L,C9,Q4J6I+0H%9A)352E"3'[,99"3C.9)^O!2  +*1\P#5X3H
M4 D3@X(0&Y6:UMN@9J$O2$.7\EW!PH2C7L%:Y:]2:U+B:4;PN*GU]9[DD;NN
M'R5/> 3NI6HO546J1AL@50=\4)DQO@Z.,H)BFE+NP7H2=2*WW4DC*S*7R27R
M40D@26:12^HIPK306)5+1N'FO*#5ILX=WY6;[ OU*Q!Q'?C4I4"JB-RKJP74
M72^K.FM4K='Z]5?0F.WKF\[[;YE@1\"!F*FA4,(QEL1F8BPGEEC]=O;#.3-?
MXI(DR&1;_LV4I6("(P>D/MOD>V'$J$M& @\> 2\D5%H15"6?A6(A>L(&W&*C
M7P,5U0Y;^)C/#'6;99(QA,LA12@7U!K^0W02PG_P'[<ZTV*I=+#EE6)0QOPV
M;O#R+5RZ=X'MI0J;@[HD$6WN!!,FHU&,S)X60L^U>[+-F\(GJS/V1 !=F1=.
M0@$7P86+":/(+I,[4G-.I=O_?!3R&QU0$#U-"BRW7$@$ULA>@_:>:^84;'J.
M$?:M!=*U."&\5S0AJUH0>&YID3-@G0:(E:QR&GQ6@&J7S$PQJ4LKIA >=K]"
M+#EX?YY>,*X<++"A*$^1"<'IKJ<>Y)Q1OLT+95S>8PO=JQT_)-.=,&%SASPN
M%K6%/PPI*-A:$[V*7:*L15!M!X<I+5RX5&LTL*9P6;_5&>N^,$"B1RV_!=&A
MP'H?H\PS/B.28Z2H# 3EW31S"IZT).?&%E0B[C1N*0#WYNZ1&Y;1*R^]\B+*
M2[P!RLO''-A--H(#6JWDNVR(Z]!Q7[P2/L1;B]\N%>77B?!N.1!:-R&];$D2
MS"W+^SCOPZE].+4/I_;AU.NE[K415/3>4'@PD:ICU.,BX<2!4<?9VZ<9+-/H
M&"TUTJKX"RY#^\V=^ORXR4O2GG[(6'%6.5;662E(;011S %96BX0(>%^.:F:
ME<S+$2F'BJWA>_9Z#4&03;W1MMD9''J.+F+YV%C,(.M*G(GMA::?U/AP<4KL
MPFWIZ M$I76-49M$KS 2B6N%1(W%GQ,6J!"4,%VX/Q!&@7?B)*V-H]+$E%2,
M!TB("1J_3K7S9D8HX5+Q^6Z9@X'_13N;B19VDPRA/QD%EI(*I4L1]V08J8@N
M&HKPH=>_"XV0@DVP+8W@P6 XH+_5)XCGE&[\&-T VTYB7TE&WZC#Z<[E1W+2
MQ=LJNW+MIN!H0V3PC"#+",;F8,+)+.OA;Q[4ZJ+E&B[>/=]SZKSN<I[@EH0$
MSQ-ZT#SX0CJ+O]7QF*EMC _6E2**+7:T2C/#1GE=$#T=L"':5;[#IYNV+5J8
M]6XYZ/&1CME(RV).B/#"E *.W,09V@YOMC'7;<MK8[F:JZKXY!JGCL.O)9!\
M,<="=@^#,7;+WN_>'NOM,;''] ;88^\H9 +\"*RRTGI9/3#"]3S*@O-NG8@H
MLX:5DEA.Q.\(@TN%5EQH?9A>N#2F]/"011Z')DE.8\(]-7'[PA^/;*P'^R5A
M&P/K+0R;O$WZ%3 _"ID9<<I_ZKY>P@#M]XQGN\PU>5,+52_M_6:]H:](4Z-0
M'F^5(ZX/%.1Z,GH=NIH-YYC!.9\9UB2@1Q_YH.<S:E8RV]:IJ03(FR:O7UW,
M?LK,\%G2#!C*' A6>&>"[5N9$$./R](4HXW[Q\<DT(LWW\USJ5!Y(C-F-#N9
M[SO;P^N8NYS,#5@/MNH:F T/X>MH-_3<<H[R9JC&>;.Y?NU)PV^<&_C4_PGW
M00X&1D<*MN ^IQPN3\75<,NE-*NAC"[<[3NLR5K9=.EET)W*H-$&R*!CXU<S
MO,7>Z=>-F[.J,#+N.. D[4B9B\-X67H6G&E)1*;)'+O8M>W\2*^#(9NY@*&7
M!"B1M\RE 88N#["9KPAC4KXBMBO-RX6@TF(L%Y.!BPN#^XJQF_;ZFXF,.-A4
M?4VF]33(:BH:P[#&<N0ZCNY<B4^'?_FVC\(>,BJ:.^YY9<XR\7I9IZTP@WWY
MGNFV!NG@^O,7F%!=Q26'$G_N\!6W0?^2TKEGAA1%XBK,Q!U%[QB"OC&=,?UH
MJXV*T!!-=+2+G#*QZM(I)B*HV-^]<.4(H<Z4RG4/VLP^:@_GB^B6<):7E97I
MZ8)_-?#%>DGSAY4TXPV0-()D(P;'JO)D*?]L>2/0O$DD'7U_;R_<X_];QE#Q
M*CWO> CX(S".@IJSY=16"^0!")1:!W_>V\7RY)DN^/F&"+#NUV;5"Z6E=B>X
M-U>SF+5/(2K%?89(3_=&OD1=G7@[@PE1$W/C\I#\3U+H3>4!/Q<G7&EM.I@U
M:@D&:Z3D-TBY/#5F41AW).8;F>SEYN\&'[V^RRM6!?B'X1(S,.6-C3Q:<;UY
M^?[6R&PE_<N3PD7GG$VS\![REA$!&$P4B$#F]5TT&-E,7MH'-?N@9A_4_*,$
M-?_@:M!D ]0@3^B^]CQC9[9N]2:)Q.SP0C6@,#5_9331,7KA0L*J+$._--;E
M]=G0[I4^-/,N5XS38;3@QS[6MM\,M\M=NO^4_*5%L/]\*]YVJ9;&ZSE'6QQ$
M=:1M/UT/\I)"RZ3&$$HX3$LZ3$I>M971JIE7"\90J^<*3 D7RX,9-6J;874L
MS*']8J''K_XZ@3M?28=ZR<UV9&V40@W1 @0%D]JZ5@SM(-TM?3]D8+50&$Z>
MDF7=-F*4.XWK8?V@.4IN9@S$*5"]D:CL!XDT:D 82:7\6.IU:7(9&,F0XM8C
MX]I%>GF'V-2=^+KP#':V<,TS9TG1T.?H>?L>T&6-YIL4?CD4GAZIAFTJVFCK
M2U)PIR;=+!V[WGQ?O FHL%O;/#0ZKW-,-*%"0(TD8H3&"!"ZU%E5U-KS>U,O
M8:_M:\1!EVE225"4'?7M9UI7G1Z*[7G$'L8VFYW^IDN?<_S'.A%,D;W@DX@%
MD^+ILB7$C5ZFS#QL3%O4='0ZA:0^3Y,R96P!9G CRQR]][4T<,$BCKL-J)7V
MU?.9"*@1E_=[.WUUCQXW)8,C1>/*6QQ;H%Q\TY*I<G$:>Q/0?T<!F8YU.RO+
M=NCM\)@V\>*]+O,11N'Q%+D5^HGB,R8476JQI/%X\<6.Z\+P.F:QN) +3!^/
M@ZU;YD>_# 8G:S$BFQNO;#JV*U-QD/[&Y.T^4RQOX SJ)A>7H2EOJ<X4\'Q"
M]>T: ]^-AU@N+!VX49Y7/*@O@'")XG962<$ME]$GN_R85HW+8#3"KJJ2A/T&
MI&O0G6Z482HQ:V,K8HDC&LGKCCEE4M##F /B.8LC50(-T_RRM$.8(U$AUY*>
M5I*2$K;3/AP-'>5"Y"RLHH4(3":K#TG\[VBJ@<(D)B]QJD_CZ#5ZT>B3#=#H
M;;+1(8.$OP8V+,XZ..E'%WS*WTN;6\E ?*M!T<MG*VO\9XFHC%ZK=!">>5F1
MQI5=RZ"LI$1!T042XOBHFWS7<Q+O\!J>8S$;97B&01YQV3LG=\9ND<Q$\1<3
M%3/'Q610RN_ZIIRNT 5+?(L(>3$LN28M&C^T;#7U-F(+V34(-YVU,QN]DKBM
MP3;E66 QWQSU!*FLBJ("'8PXWZPD'")YG5 -)'-"4$.8#<,,T*\X-T*6!/=,
MP4;."HQN2HW#UIOMQE3;J3U#Y-.CE$DE;VP[HSL/@F^*H2SRX)1X)),00N%
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M3Q4;H,90^2SBP;!1XL&TK!I 06R6 J$E712C65"92X6E-O&11I_RD%TR(T*
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M#'Y!JB*UCF%?/G]\?W1V1AL8G'P^/?L\^(AD"$X_PZ31(F5ZGPV.W^)*[[L
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M!/V_M?;,#=G97>]D("E3G:@*XTSO,J9L3J2STG@V)RQ[/Z*[(9I:/X1/:_O
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M9Y @)NQ7'P4S#3^-S =+N>T@0^*P\?&26Q]K42FC_>WV@Z)=^$ ;6^'VUKY
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MR)R)>WJV9H)I1LR,P\7?I-XE+"L$R)N':;FRS&DE[=<U0\Q]D+K*9"&[.3:
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M[2^'*WW75SI>SWW9K*I8NGEU4)(EW I\NQA-HZ*:X,444YM""CVRA!LF9C]
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M-&K"S;1<"+F7GP)FWAAF,^-#1*E,,W.G[L9);;"!5C.W]>.UMT)XNR &"DA
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M)*>OX-SL\BEZ1V#>V@TPOZ$S=SA*)-^&%SE(86]";P'8 "HL=Q?<(4#X9H?
M<B.T[K[6!C7BHT&H-,"'DLDXQ(Z)\D+PJ;"U)R<3: D#*V9=HC6>%9DZ@],!
M538(-F<Y2BOF,0!>0+7<J['X!?T"F2BR?WA ?#H#K%9R8H=R0(@+]E-7#._:
M)>73%(!\"<0W")(-;LYM;&PCF :-J8 ><'CD'*JOG=&\CEG#ATQ**=N(YW/&
M@LM)"<PNS(S$3'F6%:W&QP,8G$UX,D$5:-,.=I*C1A6X3'[[_?P&9T?/0J[A
M-G"F1EQ(NM0:VSJQ7W)/JT*>>7Q;C=7'%XZ/1W68'27XI4 0]MN-Y=-4W%4N
M[B0*GI-DKG6R=#!I8-*02"X6:=^Y;5.:$5L3B)SO !YS@? D>/8*MPTV=BRE
M3P)J#3Y):!Q',V?50@\Y L<? QML$N-6 7@H %P,-+A/ 32;V:8X+HI*","'
M!J.A]TR7._E>#<+V;AB$R^Y+:1ENR<<OP'5N,<P=3"%)1!W04T'RY&J[D9&F
MD_CAZ,>U5@<YP]"MI%&Z8"-CF-*$IW7H],3"7.YVZZ&$?L)('PC:R.NNY5IO
M,7H .#SWKP.NM"&^ KWX0 _.K5B,*^QW4KW[J 9=$78I\7=[SI TN!W:4(<H
M=O.D8F,)GPK&5DCO7'QHG@. 25D:_<KD* T;@1+F$D]+VLYC>'8 U=#0^IP9
M6F"'V^2-C!CF$SS%[)ZC>0ZZUP 3G#C!,*GIE<E=9F!_<18ZNTLC_-C/9Z!O
M2.9;H63J5))TXH7KY7)4S!\MT#6'@BP[X(AW1B"V%(D% AC2TI9-9U=32NO6
MI+6?J$Q(_23+2SX"$A6"94[S0*#;0B;&=+QL'PJ0=L.IL_T6G+\\UKKHIKK!
M4,#S 5'Z%D:RTFME&7P,WRYDE@UL3Q$T"3E(B2=%  AM,OB4.O,TQHH*XW*V
M<!+SO&OI4[Q[2_1P-RQ16TU)K=]$+NYC)C33NV>-/JB^7*B3M,6:<&WDQ-5K
M%LHF7Z-(TK.ALHS(UF%:)MG(JR0?H;BU*<7N=ZBRL4;4NQTK"9N_)",%?BP^
M")V8X<SV8*6?&ZO8EMXJE+"F=XH5K,NUL3' :W6D&+VM6A.Q2Z,IJ-AT#X[!
MMC[\>#*2"L0U+6=M+-6\OL]*VFVHTPOJA:E>*L2==0S:BX\B9\ZAC2:GPMYW
ME328X91*L!D)&-,5(JU%!+96P+2V9=7V@8NTV&>F !+S1RQ%"V+9Q.;5/Q.*
M>ERC5@3W*G;/7,"\U';O5=MU=D/;]5.C<_<TW)O$G]4U%5DP=\)<K@A0"',^
MSG#6,#<UB<KC\W.CW.;J"U4-""!<))DMS8(@Q2^,/230P V<0*O(.9(49, M
M99\?K(GD5^ Y-+@>(*.;GT[ D%<<J! KG-7<#;9!I.6!<+DPF)TNYD67)G<_
M2]A[K[!WM!NP][.\8TJ@YWU)IR7VO3KVH>=O6>X"3(@1 &;:J.3IZFLDZ ^I
M;FTP028FK>5%"$)3;AYK@*;0/P^1E4FM=XLRGW8#9<[5B)O2OMHBQIP#EJ"T
M@MT!?AK:0PIA16,\%"P3GX-)I)CPT"-30"< /"(&0 ,Z?@)[".;<MC0TN1:S
M @Z^7S3#6DH3+2#5KTGD*G0*>YPA%XZB!'4OY))>2+-(>D].)EB?XV+L8#&1
M_?8!+-2-(,%%I'$LN0V0KBCSU)3[;N*TABBB>>D0+:QCOOX,.BLYB (?+J4F
MYV+,(N1A#S8'S$;!:<'0'.%;$%@!S$6>$7!NM0DQS8$UM,[%79S:+2R]81-I
MF"J!;=#YR+ '6)?@:+P0XXCK,.TW15Q?1Y#=$+O0K.97+E3'EI#_7B'_>#<@
M/ZMCN+"^68GZ6ZMBR+)>Z3L(U+L5<@J8/&:NJ@D=4 =.%CPR?]1JB3LF*%RF
ME5*PK#2?A?J#6HAS=7.K7H< OSP">Q.U0/$U R:LKTTQJ+BZ(I\K^PZ%+HLG
M_R9'(XG!$& ^JGY;PX&5K44YP)1\8N.Y\,&>YZQ&P$E&,=59 3U)HPIA^*ZE
MDH)[J#C3F$AEY7L9^1N&-JJ3C/Z$KFGLUTJM#+[IE^B^C579]).QL)!EH%PF
MQ[Y]&6O6S2Z**\$#D.:9,/5B$P5B,;U$$R,7LTOVSD+NQV67BIF?Y=P>L9+R
MPYY+R.'WNRCX\;.U+A5TN517.L#AYUKSZ&.18>E4&?/>YH;4C6\I!+;KF +I
MK;WG4-MIU([;;XC:O;/?F +K6R6@B&8R4;KR@,JZW<QR0W=D0Q_][@?RC>_L
M,RC\5&M^>D,$@MT_Z_Y%4@[;M:/./.&?5A<TXWMB70J2>25OB-:ZKI.A5 FY
MIK>\E-6=D]5K.F$OE-8W1$TFB;04Q=T3Q2%^K>#[D<4;Q33W"V_]EZ*X,Z*(
M=0GO1Q+7?T]B+I)UZZMF=9.OO<PWXMJ_6U\^6V<ZOQ.%Y\HP.$B'ZV2X4"I:
M&!_3;T$DIQDGL\_5J:)QUY6Y3H%M3Y:?II:OG3AK2D=@!">&O4I]\K-.TP;8
M5Z@_W@@'UP)'R?378'JG^01>EVS?C.V;FC=/8<W;-F\V#3V!,?>VK(-SST/[
MP,]39[:<BLZ+KVPIJBT_?6@2E7N]4WN][BMD]NT7088T"NP7=QK-HF#AO4#7
M[N#E$<G=%H*7Z_$="DBFRG'' I(/OI*Z%-E=$]F7Q"6?M.C^=FI*@=QY@7Q1
M=/+M263OXI=2!G=-!E\2EGQ[(KC38<GRG?HT>K'U=^I?^@+]G>3^4^_/U]U_
M6F7_%ZRS_P-02P,$%     @ Y$DQ60>Q]_AF%@  F%0  !@   !C87!R+3(P
M,C0P.3$V>&5X.3ED,2YH=&WM7/M7V\:V_E?FIB^REFT,A#P@S3H.D)ZT(:%
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M^V-CX7E"BW%XK67[I1'\_[H1_'&?*OX>+=A/B.O1A35I871L\)1J:ACA(GU
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M^NVZ9 *@#6\-L$009C)0VL'1EVU7EH>9YG&2+G12PR[LQ&F/9BXWK"B;UT;
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M=/?IX,GVD\'6D]W=.^T7_*?-@4L#CGVD-[#I_^0F_PW/%_\&4$L! A0#%
M  @ Y$DQ6<>&<-.- P  S0P  !$              ( !     &-A<'(M,C R
M-# Y,38N>'-D4$L! A0#%     @ Y$DQ6<' 12II!0  \#L  !4
M     ( !O ,  &-A<'(M,C R-# Y,39?;&%B+GAM;%!+ 0(4 Q0    ( .1)
M,5DG_$[ <00  .TE   5              "  5@)  !C87!R+3(P,C0P.3$V
M7W!R92YX;6Q02P$"% ,4    " #D23%9RI9>.?\<  #]R0  %
M    @ '\#0  8V%P<BTR,#(T,#DQ-G@X:RYH=&U02P$"% ,4    " #D23%9
M%E\Y\O!B  !\_P( &               @ $M*P  8V%P<BTR,#(T,#DQ-GAE
M>#$P9#$N:'1M4$L! A0#%     @ Y$DQ6;K=W&?-0@  N0D" !@
M     ( !4XX  &-A<'(M,C R-# Y,39X97@Q,&0R+FAT;5!+ 0(4 Q0    (
M .1),5G/\^@^!@T  -IK   8              "  5;1  !C87!R+3(P,C0P
M.3$V>&5X,3!D,RYH=&U02P$"% ,4    " #D23%9!['W^&86  "85   &
M            @ &2W@  8V%P<BTR,#(T,#DQ-GAE>#DY9#$N:'1M4$L%!@
0   (  @ 'P(  "[U      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>capr-20240916x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="capr-20240916.xsd" xlink:type="simple"/>
    <context id="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
        </entity>
        <period>
            <startDate>2024-09-16</startDate>
            <endDate>2024-09-16</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Tc__u0mS83JvkawhwhGBn5PqA_1_1">0001133869</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Tc_A0isA7WEhUag8SFS4MovyQ_2_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Narr_hioGD5x-_kigBtJzNsz5Zg">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Narr_Et_S-skv9kORqx98fSLjSA">2024-09-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Narr_WmmFSHtzyEy3wbHiyAiBVQ">CAPRICOR THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Tc_xkxd5fdwwEeSO-0tcAXBPQ_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Tc_MF7c9jfp7ECE0x2FIG8v4g_1_2">001-34058</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Tc_EWLYZfCzY0CkOuwRtw7whg_1_4">88-0363465</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Narr_6Gwhytn1jEeQgZuucnTI_A">10865 Road to the Cure, Suite 150</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Narr_8bWrczrZqUK0z4S0x8Kcpg">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Narr_qqv1dUPhU0i7q-WC-1YBug">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Narr_WUmy4J3yFUutLlFcNnh1Qg">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Narr_8nF0O_Tw9Uen4tHeMYagYg">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Narr_qfdm4xQIfUGFm5RNqOK-qA">727-1755</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Narr_ryqJ-MZvREaCKewdnI0nFg">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Narr_0IQtqsohekSxngTDnPDHdQ">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Narr_Mm-3FuYyJEKQWym5f08LWQ">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Narr_lAy6w3bZxECd1mo03_IQZQ">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Narr__Do9PBQPeUa_MsH8cx6j1A">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Tc_kDYCiCuE2U-QkViyARS4oQ_2_0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Tc_70pryl74Ck6eGE8pZmr__w_2_2">CAPR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_9_16_2024_To_9_16_2024_js4eh2bx5EmpEZVal_9Ajg"
      id="Narr_tt6wqBb86UGfl7LQUlhTSw">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
